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Abstract 
Perineural invasion and spread of cutaneous squamous cell carcinoma of the head and neck 
(cSCCHN) is associated with worse prognosis and high rates of locoregional recurrence. It 
occurs in less than 5% of cases, but given the high incidence of cSCC in Australia, portends 
significant morbidity and mortality. Primary tumour biology remains poorly understood and 
precise molecular mechanisms by which malignant squamous cells invade and progress axially 
within the perineural space remain unclear. Thus, there is no targeted therapy for perineural 
spread of cSCCHN or other neurotropic malignancies. Dysregulation of cell membrane 
receptor trafficking is a hallmark of cancer and such receptors are potential therapeutic targets. 
Over-expression of the epidermal growth factor receptor (EGFR) is well described in squamous 
cell carcinoma and the monoclonal antibody cetuximab is approved for advanced mucosal head 
and neck SCC. Other members of the ErbB family (HER2, ErbB3 and ErbB4) are less well 
understood in SCC. The erythropoietin-producing hepatocellular carcinoma (Eph) family of 
RTKs is similarly dysregulated in a wide range of cancers. Given their physiological roles in 
neural development and skin homeostasis, these receptors represent other potential therapeutic 
targets in perineural spread. The aim of this thesis was to investigate the expression and cellular 
distribution of molecular receptors involved in perineural spread, particularly those with 
targeted therapies in development or clinical use for other indications. Four SCC cell lines and 
one human keratinocyte line were examined by immunoblotting and immunofluorescence. 
Human tissue specimens of perineural spread from cSCCHN were collected over an 18-month 
period and immunostained for EGFR, HER2 and other cancer biomarkers. Ki-67 proliferation 
index was examined for the first time as a potential prognostic factor and marker of 
aggressiveness in perineural spread. Cell cycle regulators p16 and p53 were examined as novel 
biomarkers and to shed light on possible non-RTK dependent mechanisms implicated in the 
disease process. The work with p53 builds on recent data published by our collaborators 
suggesting dysregulation of the p53 pathway in clinical perineural invasion. P16 is an 
established prognostic factor and surrogate marker for carcinogenic viral infection in 
oropharyngeal SCC not previously investigated in perineural spread cSCCHN. To our 
knowledge, this is the first study to demonstrate over-expression of the EGFR in perineural 
spread cSCCHN, in 90% (n=18/20) cases evaluated. This suggests a potential mechanistic role 
and reveals a valuable therapeutic target. Moreover, half of these cases had strong plasma 
membrane expression in the absence of cytoplasmic labelling, consistent with dysregulation of 
receptor trafficking and RTK escape, a new hallmark of cancer. Conversely, perineural spread 
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specimens were uniformly HER2 negative effectively ruling this out as a therapeutic target. 
These findings will have implications for treatment of advanced cSCCHN with perineural 
spread of carcinoma. Patients with recalcitrant and/or resistant disease could be offered existing 
anti-EGFR therapies or enrolled in clinical trials testing novel or combination therapeutics. 
Ultimately, we aim to improve survival and quality of life for sufferers of this morbid form of 
tumour spread. Our findings may also have implications for other neurotropic malignancy, 
including pancreatic, gastric, colorectal and prostate cancers. 
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1.0 Introduction 
 
Cutaneous squamous cell carcinoma (cSCC) is a malignant proliferation of epidermal 
keratinocytes secondary to the mutagenic effects of ultraviolet radiation.(1) Australia has the 
highest incidence of cSCC in the world, with the disease occurring predominantly on the sun-
exposed head and neck and in males due to occupational exposure.(2,3) Other risk factors 
include age, fair skin and immunosuppression. With ongoing ozone depletion, an ageing 
population and increasing survival of immunosuppressed patients, the incidence of cSCC of 
the head and neck (cSCCHN) continues to rise.(4,5)  
 
In 95% of cases of cSCCHN, complete surgical excision is curative.(6,7) However, there is a 
well-recognised metastatic potential, with reported rates of regional and distant metastasis 5% 
and 1%, respectively.(6) The disease-specific death rate is at least 1%, with a recent systematic 
analysis reporting a range of 1.5-2.1%.(7,8) Although metastatic and disease-specific death rates 
are low compared to other malignancies, the absolute number of patients with cSCCHN means 
there is paradoxically significant morbidity and mortality associated with this disease. 
 
Australia has the highest incidence of cSCC in the world with the most recent age-standardised 
rate reported to be 387 in 100,000 and the rate in males exceeding 1300 in 100,000 in far north 
Queensland.(3,9) This rate has more than doubled over the preceding 20 year period.(4,5) In 2016, 
it is estimated that 560 Australians will die from non-melanoma skin cancer (NMSC), the 
majority from advanced cSCCHN, with an age-standardised mortality rate of 1.9 deaths per 
100,000.(5) The estimated incidence of cSCC in the United States is 700,000 cases per year, 
with associated deaths estimated at up to 9000 annually.(8) The incidence and mortality is 
significantly higher in the immunosuppressed population, including organ transplant 
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patients.(8) The annual Australian economic burden of NMSC is estimated at $500 million per 
year and is expected to more than double by 2020.(10) 
 
Perineural growth is an under-appreciated and distinct form of tumour spread seen across a 
range of cancers. Perineural spread is associated with both pain and worse outcome, 
independent of vascular or lymph involvement, in NMSC and cancers of the head and neck, 
pancreas, stomach, colon and prostate.(11-13) In the head and neck, perineural growth comprises 
two distinct entities: incidentally detected microscopic perineural invasion (PNI) and clinical 
perineural spread (PNS) along larger, named nerves with clinical and/or imaging evidence of 
involvement pre-operatively.(14) Perineural spread is also referred to as clinical PNI (cPNI) as 
distinct from microscopic PNI (mPNI). Clinical PNI or perineural spread describes tumour that 
has spread away from the primary site and thus represents a unique form of metastasis.    
 
Despite its prevalence and prognostic significance, the molecular mechanisms underlying 
perineural invasion and perineural spread remain poorly understood. Moreover, no reliable 
biomarkers have been identified. Thus, no targeted therapy exists for PNI or PNS in non-
cutaneous or cutaneous malignancy and the ability to risk-stratify patients is limited. An 
improved understanding of the molecular profile of perineural spread and therapeutic strategies 
targeting the tumour cell and/or the nerve microenvironment would be of immense benefit in 
treating and prognosticating this aggressive disease.   
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2.0 Literature review  
2.1 Defining perineural growth 
Tumour neurotropism in the head and neck was first described as “invasion of tumour in, 
around and through peripheral nerves.”(15) These nerves were theorised to pose a physical path 
of least resistance to invading malignant cells. Another early proposed mechanism of spread 
was via endolymphatic spread within the perineurium, as an extension of lymphatic metastasis, 
but the absence of lymphatics in nerve tissue was later demonstrated, disproving this theory.(16)  
 
The peripheral nerve is composed of many nerve fibres enclosed by a neural sheath comprising 
three distinct layers (Figure 1).(17) Endoneurium is the innermost layer of loose connective 
tissue which envelopes individual nerve fibres (axons) including myelin secreting Schwann 
cells and capillaries, forming nerve bundles within the nerve fascicle. The perineurium, 
comprised of multilamellar, concentric perineural cells and layers of basement membrane, 
invests each nerve fascicle. The epineurium is the external fibrous sheath that envelops a group 
of nerve fascicles to encompass the whole nerve in its entirety.(17) The perineural space is thus 
a potential space located between the nerve fibre bundles and the surrounding perineurium, 
which can provide a conduit for tumour spread. Electron microscopy of the perineural sheath 
reveals that it comprises concentric laminae of perineural cells joined by tight junctions 
(zonulae occludentes), vested with basement membrane on both sides.(18) Longitudinally 
disposed elastic and collagen fibres together with fibroblasts occupy the spaces between 
laminae.(19) It is this sheath that effectively forms the selective “blood-nerve barrier” that 
separates the peripheral nerve compartment from surrounding tissue. 
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Figure 1 Peripheral nerve shown in transverse section consists of nerve fascicles (F) 
invested by perineurium (P), which is composed of concentric, multilamellar perineural cells 
(Nu). Endoneurium is the loose connective tissue encompassing individual nerve fibres, blood vessels 
(V) and myelin (M) secreting Schwann cells within each fascicle. Epineurium (E) is the loose 
collagenous tissue sheath encasing the nerve as a whole. Adapted from Wheater’s Functional Histology, 
5th edition (2006).(17)  
 
Mechanistic understanding of how tumour cells enter the perineural space and traverse along 
it remains poor. It is thought that in cutaneous malignancy undergoing clinical perineural 
spread, tumour cells likely enter the perineural space in the subcutis where the perineurium is 
thin or absent.(14) Once within the perineural space, the perineurium acts as an effective barrier 
in limiting tumour cells to within this space as they track along the nerve. On the other hand, 
incidental perineural invasion is a more commonly seen entity detected by microscopy. One 
postulated mechanism in pancreatic cancer is of neurotropic tumour cells breaching the 
perineurium to access the perineural space (Figure 2).(12) Pathologists at our centre have not 
observed this perineural breach in the head and neck with cutaneous malignancy, except in the 
context of indiscriminate invasion by a large tumour bulk. This third and final group to be 
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distinguished in the head and neck is such patients with advanced local disease that extends to 
the skull base and by virtue of the aggressive tumour biology indiscriminately invades nerve 
tissue.(14) We consider this indiscriminate invasion to be an inherently different process from 
clinical perineural spread,  where tumour tracks along a nerve away from a remote, previously 
treated or unidentifiable cutaneous primary index lesion. These separate clinical entities in the 
spectrum of perineural disease are discussed further below. It may be that different physical 
and molecular mechanisms are involved in these related but distinct processes or alternatively 
that a common underlying mechanism exists and large-nerve clinical perineural spread is an 
end-stage result of microscopic perineural invasion that first occurs in the subcutis.     
 
 
Figure 2 Exploded diagram of three-layered structure of a peripheral nerve showing 
tumour cells breaching the perineurium. In pancreatic cancer it is thought that neurotropic tumour 
cells breach the perineurium to access the perineural space.(12) Neurotropic factors in the nerve 
microenvironment, such as nerve growth factor (NGF) and TRKA (tyrosine receptor kinase A), are 
thought to play a significant role. Figure adapted from Bapat et al (2011).(12)  
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In histopathological terms perineural invasion is defined as presence of tumour cells within the 
perineural space (Figure 3).(20) However, encasement of more than 33% of the nerve 
circumference or tumour cells within any layer of the neural sheath is considered highly 
suggestive, if not diagnostic, of PNI.(21) This form of perineural involvement is not evident on 
clinical or radiological examination and is established by microscopy. Small, unnamed nerves 
are involved and this process is referred to as microscopic or incidental PNI.    
 
Perineural spread (PNS) is defined as contiguous extension of tumour cells along the perineural 
space away from the primary site.(21) This is seen predominantly in the large named nerves of 
the head and neck, most commonly in branches of the facial and trigeminal nerves, consistent 
with the high incidence of cSCC that occur in these sun-exposed dermatomes.(22) In a recent 
analysis of 120 patients at our institution, no known or assessable primary was found in almost 
half the cases.(22) In this cohort 22.5% of the patients presented with PNS from an unknown 
primary tumour (T0) while a further 21.7% were unable to be assessed (TX) due to a history 
of multiple potential index lesions and/or non-surgical treatment of these lesions. Furthermore, 
in cases with an identified likely index lesion, more than a third had no microscopic perineural 
invasion reported on pathology, indicating that clinical PNS is not necessarily preceded by 
microscopic PNI and/or there is significant under-detection or under-reporting of microscopic 
PNI in primary cutaneous tumours.(22) 
 
Perineural spread of carcinoma is associated with symptoms including loss of function, pain, 
numbness and formication (a sensation of ants crawling), however these are commonly missed 
or misattributed by clinicians resulting in diagnostic delay.(14) At our institution the median 
time from an identifiable primary tumour to the onset of PNS symptoms is 16 months, 
reflecting the typically slowly progressive natural history of the disease.(22) The average time 
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from symptom onset to diagnosis is 6 months, indicative of the not insignificant diagnostic 
delay associated with the condition.(22) Tumour spread can occur distally (centrifugal) or more 
commonly in a retrograde fashion towards the brainstem (centripetal), culminating in central 
failure. The visualisation of skip lesions consistent with non-contiguous spread along the nerve 
has previously been described and the concept propagated in the literature.(23,24) However, we 
consider this likely to represent tissue-sectioning artefact, with a recent histopathological 
review of 49 patients treated with surgery at our institution demonstrating no evidence of non-
contiguous spread in 50 separate cases.(20) Magnetic resonance (MR) neurography detects 95% 
of PNS and is used in pre-operative planning for resection margins (Figure 4).(22,25)  
 
Figure 3 Haematoxylin and eosin stained tissue section showing perineural spread along a 
cranial nerve. Tumour cells are seen within the perineural space (arrows) consistent with perineural 
invasion. Areas of intraneural invasion (arrowheads) by tumour cells are also seen. Image from Warren 
& Panizza (2015).(26) 
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Figure 4 Coronal magnetic resonance neurography showing thickening and enhancement 
of the right infraorbital nerve characteristic of perineural spread from cutaneous squamous cell 
carcinoma of the head and neck. Pathological right infraorbital nerve is indicated by the arrowhead. 
Image from Warren & Panizza (2015).(26)  
 
2.2 Histopathological features of perineural growth 
Standard haematoxylin and eosin (H&E) staining is sufficient to identify perineural invasion 
and spread in most cases (Figure 3). However, in borderline cases where there is clinical 
suspicion yet no obvious PNI, staining for broad-spectrum keratin (AE1/AE3) or cytokeratin 
to label epithelial tumour cells or for S-100 to label myelin secreting Schwann cells, can assist 
in defining the pathology.(27)  
 
Several studies have used a single immunostain to enhance nerve detection and thus 
identification of tumour cells in the perineural space. Several more recent studies have used 
double immunohistochemistry staining techniques and demonstrated a significant increase in 
detection rates.(28) Recently, p75NGFR immunostaining was shown to increase the detection rate 
of microscopic PNI compared with H&E staining alone.(28) The authors suggested 
p75NGFR could serve as an alternative to S-100 or be included as part of an immunostaining 
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panel for PNI detection. Another recent study demonstrated that dual immunohistochemistry 
(IHC) staining with S-100 and AE1/3 increased detection of PNI in NMSC compared to H&E 
alone, however the improvement in detection was almost exclusively seen in SCC cases with 
small nerve PNI.(29) It was suggested that IHC staining helped distinguish true PNI from 
classical mimics, such as peri-tumour fibrosis. However, in this study only clinically suspicious 
cases were used giving an obvious selection bias. These special staining techniques may be 
useful in detecting or confirming incidental microscopic perineural invasion in primary lesions 
or in advanced tumour masses, however are usually not needed to histologically confirm large-
nerve perineural spread. Perineural invasion is now a core item in national clinical guidelines 
for standardised reporting of cSCC and a staging determinant.(27,30) Use of IHC is not yet 
routine for detection of mPNI but is available and performed in some centres.  
 
An important study by Frydenlund et al (2015) took 57 cSCCHN and 53 cSCC from other 
locations and analysed for perineural invasion and TrkA expression.(31) S-100 was used for 
nerve labelling and p63 for nuclear labelling of tumour cells in their novel double 
immunostaining protocol. The authors demonstrated an increase in detection of PNI in head 
and neck specimens from 11% to 23% compared to H&E alone, representing a 2.3-fold 
increase in detection. Panizza et al (2014) conducted the largest histological evaluation of 
cSCCHN with PNS to date, of 50 tumours from 49 patients.(20) Specialist dermato-pathologists 
characterised the tumour invasion pattern after assessment with both longitudinal and 
transverse sections, achieved by mounting dissected nerve segments into cassettes to preserve 
the respective axes. Consecutive processing of transverse and longitudinal sections allowed 
complete assessment of the nerve and maximally eliminated processing artefact. There was no 
evidence of skip lesions with perineural tumour spread contiguous in all cases. Coexistent 
perineural and intraneural invasion was the predominant pattern seen in 98% of cases.(20) This 
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finding suggests that tumour cells that have invaded and are traversing the perineural space are 
not confined to this space, but in almost all cases invade into the nerve fascicles. Alternatively, 
it could be considered that tumour cells undergo intraneural invasion first in the subcutis before 
spreading to the perineural compartment where they are confined by the perineural sheath. 
Either way, it is considered most likely that in cases of clinical perineural spread it is the 
intraneural involvement that causes the characteristic symptoms and signs.(20) In the 
aforementioned study, only 3.9% of specimens demonstrated epineural involvement, which is 
thought to reflect the multilayer barrier function of the perineurium beyond the superficial 
fascia, effectively limiting tumour cell migration beyond the nerve compartment into 
surrounding soft issue. The perineurium thus provides an adequate resection margin when 
tumour is confined to the nerve macroscopically.  
 
2.3 Epidemiology of perineural growth 
There is variation in reported rates of PNI and PNS across the literature, likely due to the 
absence of a standard working definition for each of these pathologies.(20,27) There is also likely 
variation in awareness levels and rates of detection across different geographical regions.  PNI 
occurs in 2.5% to 14% of cases of cSCC, with most studies reporting rates < 5%.(32) Cutaneous 
SCCHN has a particularly high propensity for PNI, where it is an aggressive feature, portending 
an increased risk of locoregional recurrence and reduced disease-free survival.(33) In one series, 
3-year disease-specific survival for cSCC with and without PNI was 64% and 91%, 
respectively.(34) Large studies by Goepfert et al (n=967) and Leibovitch et al (n=1177) firmly 
established the link between PNI and tumour recurrence, distant metastasis and reduced 
survival.(8) A study by Lin et al (2012) showed 5-year disease-free survival (DFS) of 78% with 
local failure of 40% and regional relapse of 29% for cSCC with PNI.(35) 
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In comparison, the incidence of large nerve PNS at our institution is 1% with other series 
reporting similar rates less than 5%.(36) It is proposed that the high incidence of cSCC in the 
chronically sun-exposed anterior face and the proximity of large nerves with rich ramifications, 
plays a significant part in their involvement.(37) Clinical PNS has worse prognostic influence 
than incidental PNI, partly because it can preclude obtaining adequate oncologic resection. 
Five-year local control rates are 25-38% versus 80-90% for clinical compared to incidental PNI 
following treatment with surgery and/or radiation therapy.(37)  Although perineural spread is 
rare, given the high incidence of cSCCHN in Australia, it portends paradoxically significant 
morbidity and mortality. 
  
Perineural invasion is also described in non-cutaneous malignancies, including head and neck, 
prostate, pancreatic, gastric and colorectal cancers (Table 1).(12) It has been reported in up to 
80% of mucosal head and neck squamous cell carcinoma (HNSCC). Adenoid cystic carcinoma 
(ACC) of the salivary glands also has a particular propensity for nerve invasion, with up to 
62% displaying perineural invasion.(38) 
 
Table 1 Cancers in which perineural invasion (PNI) has been reported.(12) 
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2.4 Current treatment approach to perineural spread 
Cutaneous SCC with incidental PNI is treated with surgical excision, with consideration of 
adjuvant radiation therapy depending on the existence of other high risk features.(30) The 
current standard of care for clinical PNI or perineural spread is an appropriately designed en-
bloc surgical resection with post-operative radiation therapy.(37) This approach has led to an 
almost doubling in survival rate.(34) Previously, for cSCC with clinical PNI treated with 
radiotherapy alone, 5-year DFS was 39%, with a pattern of predominantly local relapse. In 
comparison, 5-year locoregional control was 64% in a homogenous series of patients with MR 
imaging positive or histopathologically proven PNS treated with surgery and adjuvant radiation 
therapy.(37) However, significant morbidity can be associated with the often extensive surgical 
resection required. In advanced skull base disease, palliative radiation therapy is recommended, 
given the significant risk of leptomeningeal dissemination. 
 
2.5 Future treatment options   
Cetuximab is a chimeric (mouse/human) monoclonal antibody targeting the epidermal growth 
factor receptor (EGFR) that is a first-line treatment option in combination with radiotherapy 
for locally advanced cSCCHN.(39,40) Other monoclonal antibodies are in development or trial 
targeting a range of markers in advanced cSCCHN. However, there is currently no targeted 
therapy approved or in development for perineural spread as the molecular mechanisms have 
not been sufficiently elucidated. Targeted therapies may have applications in reducing the 
morbidity of surgical and radiation therapy, alleviating neuropathic pain, augmenting current 
therapeutic strategies and providing viable treatment options for currently palliative disease.  
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2.6 Molecular mechanisms of perineural spread 
The mechanisms of perineural invasion and spread are poorly understood, especially in cSCC. 
Research has been conducted across a range of malignancies displaying PNI, particularly in 
prostate and pancreatic cancer. There is literature on mucosal head and neck squamous cell 
carcinoma (HNSCC) with some evidence to suggest that similar mechanisms may underlie 
invasion and spread along cranial nerves of cSCC in the head and neck region (cSCCHN).  
 
A variety of investigative techniques and in vitro and in vivo models have been used to study 
this unique form of tumour spread. Biomarkers and mediators prominent in other malignancies 
have guided investigation thus far. A bias exists for drug targets with therapies already on the 
market or in clinical trial with the potential to be re-purposed.  
 
2.6.1 Tumour-nerve microenvironment 
The importance of the tumour microenvironment in facilitating advanced disease and nodal 
and distant metastasis is well understood. This environment comprises the extracellular matrix, 
the immune infiltrate and reciprocal interactions of these elements with invading tumour cells. 
 
Particular characteristics of the nerve microenvironment are similarly theorised to contribute 
to and facilitate perineural invasion and spread. An increasing weight of evidence suggests it 
is the reciprocal interactions between tumour cells and neural tissue that culminates in 
perineural invasion (Figure 5). A phenotypic change in tumour cells is thought to facilitate an 
enhanced growth and survival response within the nerve microenvironment. Similarly, the 
tumour microenvironment promotes neurite outgrowth and infiltration into and around tumour. 
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Figure 5 Reciprocal interactions in the nerve-tumour microenvironment. Up or down-
regulated expression of gene products in pancreatic ductal adenocarcinoma with perineural invasion 
(PNI) showing how reciprocal interactions between tumour cells and the nerve microenvironment likely 
culminate in perineural invasion. Multiple signalling molecules from different signalling pathways are 
involved in the process. Neurotrophins include nerve growth factor (NGF) and brain-derived 
neurotrophic factor (BDNF) which bind to tropomyosin-receptor kinase A (TRKA) and TRKB, 
respectively, as well as the low-affinity neurotrophin receptor (p75NTR). The secreted glial cell line-
derived neurotrophic factor (GDNF) forms a complex with GDNF receptor-α1 (GFRα1) and rearranged 
during transfection (RET) receptor tyrosine kinase. Cell surface molecules implicated in PNI include 
mucin 1 (MUC1), myelin-associated glycoprotein (MAG), L1 cell adhesion molecule (L1CAM), neural 
cell adhesion molecule (NCAM) and the chemokine ligand 1-receptor (CX3CL1-CX3CR1) complex. 
Differentially expressed genes include mucosa-associated lymphoid tissue lymphoma translocation 
gene 1 (MALT1) and tumour necrosis factor receptor-associated factor 2 (TRAF2). Differentially 
expressed proteins include synuclein-γ (SNCG), RHO-GDP dissociation inhibitor-β (ARHGDIβ), 
microtubule-associated protein RP/EB family member 2 (MAPRE2), yippee-like 1 (YPEL1) and 
kinesin family member 14 (KIF14). The epidermal growth factor receptor (EGFR), transforming 
growth factor-α (TGFα) and matrix metalloproteinases (MMP) also play important roles within the 
microenvironment. Image adapted from Bapat et al (2011).(12)  
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A range of cell types and secreted proteins within and in proximity to the nerve sheath play are 
thought to play key roles. Schwann cells and fibroblasts are integral components of the nerve 
microenvironment, although their potential roles in PNI remain poorly defined. Endoneural 
macrophages were shown to be a prominent component of the perineural environment in both 
human PNI specimens and animal models of PNI.(41) Moreover, they are involved in reciprocal 
signalling via secretion of molecules, including glial cell-derived neurotrophic factor (GDNF), 
that induce perineural tumour cell growth. A recent study by Deborde et al (2016) revealed a 
sub-population of Schwann cells that was associated with tumour cells in mouse and human 
specimens of pancreatic adenocarcinoma with perineural invasion.(42) The authors went on to 
show with in vitro studies that Schwann cells induce cancer cell dispersion and neurite invasion 
in a contact dependent manner and that this is inhibited when neural cell adhesion molecule 
(NCAM) is depleted.(42) These findings highlight the active role the nerve microenvironment 
plays in the process of perineural invasion and spread, within a milieu of chemokines and other 
factors.    
 
A similarly novel study by Chawla et al (2016) examined specifically the immune cells and 
molecules in the perineural tumour microenvironment.(43) Nearly 60% of the cohort had at least 
moderate lymphocytic infiltrate, comprising B and T cells, and including a sub-population of 
FoxP3 (forkhead box P3) positive natural regulatory T cells. In particular, positive staining for 
galectin-1, the prototypical galectin, a family known to be involved in immune mediation, was 
found to be a significant predictor of poor patient outcome.(43)  
 
To date, a majority of research into the molecular mechanisms of perineural growth has focused 
on the neurotrophin family of peptides and their respective receptors, given their known roles 
in promoting the development and survival of the peripheral nervous system (Table 2). More 
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recently, several novel candidates have emerged. However, first it is important to consider the 
various models used by different research groups in characterizing PNI/PNS.   
 
Table 2 Meta-analysis of neuropeptides in head and neck squamous cell carcinoma (HNSCC) using 
16 independent studies. Meta-analyses were conducted as one-sample t-tests (significance p=0.05) to 
compare the expression of neurotrophins and neuropeptides in HNSCC and normal tissue samples. 
Adapted from Scanlon et al (2015).(44)  
 
 
2.6.2 Modelling perineural growth 
2.6.2.1 In vitro models 
Despite the difficulties in modelling the complex system of perineural invasion, several in vitro 
models have been developed, which has allowed investigation of factors promoting PNI in a 
controlled experimental environment. Ayala et al (2001) were the first to develop an in vitro 
model by co-culturing human prostate cancer cells and mouse dorsal root ganglion (DRG) in 
Matrigel matrix (Figure 6).(45) Reciprocal interactions between the DRG and tumour cells were 
consistently demonstrated.(45,46) This 3-dimensional system allowed observation of growth of 
cancer cells towards the DRG and simultaneous outgrowth of neurites towards cancer cell 
colonies. In 2004, the same group went on to evaluate prostatic tumour PNI cells in human 
tissue microarrays.(46) Real-time quantitative polymerase chain reaction (PCR), 
immunohistochemistry and immunofluorescence were performed. It was found that prostate 
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cancer cells in the perineural environment displayed increased proliferation and reduced 
apoptosis in comparison to control cell lines. Proliferative index (PI) was higher in human cells 
at PNI sites and in the model when co-cultured with DRG. Subsequent profiling demonstrated 
differential expression of 15 genes, with upregulation of 3 genes involved in the anti-apoptotic 
nuclear factor kappa-light-chain-enhance of activated B cells (NFκβ) pathway in particular 
noted.(46)  
 
Figure 6 In vitro mouse dorsal root ganglion (DRG) co-culture model. Reciprocal 
interactions between cancer cells and outgrowing neurites have been observed using this model. Our 
collaborators at QIMR Berghofer showed that A431 cells have a high propensity for neural invasion 
using a similar model. Image adapted from Bakst and Wong (2016).(47)  
 
2.6.2.2 Ex vivo models 
An ex vivo model was previously developed to monitor perineural invasion and spread along 
surgically resected rat vagal nerves by a range of human pancreatic tumour cell lines.(48) The 
authors selected for nerve invasive cell line clones by placing dissected segments of rat vagus 
nerve in purpose-built nerve invasion chambers placed on tissue culture plates. Cell 
suspensions were poured into the chambers and cancer cells could migrate along the nerve 
towards the culture plate. Genome-wide transcriptional analyses were employed to identify the 
32 
 
consensus set of genes differentially regulated in highly nerve-invasive versus less nerve-
invasive pancreatic tumour cell lines. The authors identified the involvement of kinesin family 
member 14 (KIF14) and Rho-GDP dissociation inhibitor beta, and correlated this with 
upregulation of mRNA levels in pancreatic cancer patients. Notably, these proteins play 
intrinsic roles in normal mechanics of cell migration. It is foreseeable that any such proteins 
would be upregulated in tumour cells with the demonstrated capacity of metastatic spread, 
perineural or otherwise, without this providing valuable insight into the actual drivers of 
perineural invasion and the mechanisms by which tumour cells enter and progress along the 
perineural space. However, such markers may be useful as prognostic factors allowing 
appropriate intensification or de-escalation of treatment in the clinic.  
 
2.6.2.3 In vivo models 
Several groups have used genetically engineered carcinogenesis-induced murine models to 
characterise the progression of pancreatic and prostate tumours that have a natural predilection 
for nerve invasion.(49) This ensures the nerve microenvironment remains intact as opposed to 
aforementioned models where PNI is facilitated or staged. These models have allowed 
effective study of tumour evolution in the context of the nervous system. However, the 
fundamental mechanisms of PNI remain uncharacterised. Orthotopic murine models exist for 
a wide range of malignancies, where tumour cells, are transplanted into the native organ of 
immunosuppressed mice. Specifically, pancreatic, prostate, salivary, head and neck and cSCC 
models have been used to investigate cancers that undergo PNI.(50)  
 
In investigating cSCC with PNS our collaborators at QIMR Berghofer were the first to develop 
a live mouse model where human SCC cells are injected subcutaneously into the cheek of a 
nude immunosuppressed mouse (Figure 7).(51) Invasion and spread along the over-developed 
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mouse trigeminal nerve ensues in up to 40-50% of tumours.(51) There is potential for labelled 
tumour cells to be followed over time with imaging and/or serial frozen or formalin fixed 
sections as well as re-isolation of perineural tumour cells for genomic and proteomic analyses.  
This model also has significant potential for the future testing of targeted therapeutics. 
 
 
Figure 7 In vivo subcutaneous mouse model of perineural spread. Mouse inoculated with 
A431 cells develops cheek tumour with potential for invasion of maxillary division of trigeminal nerve 
(A). Histopathological analysis using haematoxylin and eosin and special immunohistochemical stains 
(pan-cytokeratin AE1/AE3 for epithelial tumour cells and S100 for myelin sheath) demonstrates 
perineural tumour spread (B). Image adapted from Gardiner et al (2016).(51)  
 
A subcutaneous mouse transplantation model of perineural invasion of human pancreatic 
cancer was previously developed by Koide et al (2006).(52) The authors injected tumour cells 
in suspension subcutaneously on the midline dorsum of nude mice. At 6 weeks, the tumours 
were resected allowing microarray profiling to be performed. Another research group has 
developed an in vivo heterotopic model where tumour cells are injected directly into mouse 
sciatic nerve.(53,54) The ease of serial functional neurological and muscle bulk measures, as well 
as macroscopic and histologic evaluation is advantageous in following perineural spread. 
Moreover, magnetic resonance imaging can be performed to accurately quantify the degree of 
B A 
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sciatic nerve involvement. To date, only results with prostate and pancreatic cell lines have 
been published. 
 
Most recently, Scanlon et al (2015) developed a novel chick embryo chorioallantoic membrane 
(CAM) model to investigate PNI in HNSCC cells.(44) In this in vivo model, adjacent rat DRG 
and labelled human HNSCC cells were introduced onto chorioallantoic membrane. The CAM 
is understood to mimic the pro-angiogenic microenvironment seen in tumourigenesis and 
nourishes both the DRG and tumour cells as nerve-tumour interactions are observed. Cell 
tracking was performed and the CAM harvested after 48 hours for imaging analysis of tumour 
spread and neurite outgrowth. The authors identified the ligand galanin and its receptor GALR2 
to be novel candidates highly involved in the process of perineural invasion.(44) 
 
2.6.3 Neurotrophins and the Trk receptor family  
The neurotrophin family of growth factors is involved in development of the nervous system 
and is critical in peripheral nerve growth, maintenance and axon guidance. There is increasing 
literature to suggest that neurotrophins are involved in pro-survival signalling in many different 
forms of cancer.(55) Identified members of the family include the canonical nerve growth factor 
(NGF), brain-derived neurotrophic factor (BDNF), GDNF, neurotrophins 3 and 4 (NT-3, NT-
4) and galanin. After protease cleavage, these molecules display variable high affinity binding 
to a family of receptor tyrosine kinases known as the Trk receptors. NGF has high affinity for 
TrkA, BDNF and NT-4 for TrkB and NT-3 for TrkC receptors, respectively. Phosphorylation 
leads to downstream signalling that modulates cell survival and proliferation. In neurons, 
signalling modulates axonal and dendritic outgrowth. Immature neurotrophins bind the 
p75NGFR, a member of the death receptor superfamily, to which mature neurotrophins maintain 
a low affinity (low-affinity NGFR).  
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Much of the focus in elucidating the mechanisms underlying perineural invasion has centred 
on these neurotropic factors, given their undisputed prevalence in the nerve microenvironment. 
Findings have been somewhat inconsistent, however. A recently conducted meta-analysis 
compared expression of neurotrophins and neuropeptides between HNSCC and non-cancerous 
samples across 16 independent studies (Table 2). While not assessing tissue biopsies of 
perineural invasion or spread, the authors found that the neuropeptides galanin (GAL) and 
BDNF were significantly overexpressed whereas NGF, GDNF, NT-3 and other neuropeptides 
were not.(44) 
 
2.6.3.1 NGF/TrkA and NGF/p75 receptor axes 
NGF and its high and low affinity receptors are well studied in PNI. The NGF/TrkA high 
affinity receptor axis has been implicated in breast, prostate and pancreatic cancers with 
perineural growth and NGF is known to be over-expressed in HNSCC.(56,57) NGF was seen to 
be prevalent in both normal and tumorigenic prostate tissue in a study by Geldof et al (1998).(56) 
One study demonstrated higher intensity staining for NGF/TrkA in oral tongue SCC with PNI 
(n=21) compared to those without PNI (n=21).(57) In a retrospective analysis of adenoid cystic 
carcinoma (ACC), NGF/TrkA immunostaining was strongly correlated with PNI, while Myb 
and p75NGFR overexpression were not.(58) Dolle et al (2003) showed that nerve growth factor 
(NGF) is synthesized and released by breast cancer cells.(59) Moreover, inhibition of NGF or 
its receptor TrkA (with K-252a) significantly reduced the cancer cell growth, suggesting an 
autocrine feedback mechanism.(59) Targeting the NGFR and NFκβ pathways has also shown 
promise in a number of breast cancer cell line studies.(60-62) Locally injected anti-NGF 
antibodies have similarly demonstrated success in inhibiting animal models of pancreatic and 
prostate cancer.(59) Anolik et al (2015) reported a pattern of p75 staining in cSCC, which is also 
well recognised in oral and oesophageal SCC.(63)   
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Only two studies have looked at the role of TrkA in PNI in cutaneous SCC. The first study of 
cutaneous carcinoma with PNI compared immunohistochemistry of nine PNI-positive tumours 
(4 BCCs; 5 SCCs) with seven PNI-negative tumours (4 BCCs; 3 SCCs).(64) More intense 
staining for p75NGFR was qualitatively described in perineural portions of PNI-positive SCC 
tumours (80%) compared to PNI negative tumours. Moreover, staining for TrkA, B and C 
receptors was also more intense in PNI positive cSCC. However, small sample size, limited 
specificity of labelling antibodies and lack of quantitative evaluation limit conclusions from 
this study. 
 
A more recent study by Frydenlund et al (2015) took 57 cSCCHN and 53 cSCC from other 
locations and analysed for PNI and TrkA expression using a novel double immunostaining 
(DIS) protocol.(31) While TrkA expression was more frequently observed in cSCCHN 
compared to other sites and correlated with high-risk variants in this group, no association with 
PNI was found.  
 
2.6.3.2 NT-3/TrkC receptor axis 
The previously described increased expression of Trk receptors in PNI-positive cutaneous SCC 
may suggest a role for NT-3 and NT-4 in perineural growth.(31) Previous studies in pancreatic 
ductal adenocarcinoma (PDAC) have revealed NT-3/4 overexpression in both tumour cells and 
nervous tissue compared to normal pancreatic tissue by mRNA analysis.(65) NT-3 blockade has 
also halted growth of prostate and pancreatic cancers in murine models.(66) 
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2.6.3.3 GDNF 
The GDNF family includes neurturin, artemin, persephin and the namesake peptide GDNF. 
Secreted in the nerve microenvironment, binding occurs to specific GDNF receptors, which 
then cooperatively signal through membrane-bound rearranged during transfection (RET) 
receptor tyrosine kinases. GDNF has been extensively investigated in pancreatic cancer and 
also examined in bile duct carcinoma. Over-expression of GDNF and its RET receptor is seen 
in a number of neurotropic cancers and associated with progression in PDAC.(54) Cancer cells 
have been shown to migrate towards nerves via chemotaxis along a GDNF gradient in vitro.(53) 
Moreover, blockade of the RET receptor attenuates this effect. A recent study by Gao et al 
(2015) similarly demonstrated that artemin and its receptor, GDNF receptor-α1 (GFRα1), are 
overexpressed in PDAC and associated with neurotropy.(67) GDNF signalling axes may play 
an important role in PNI and spread.  
 
2.6.3.4 Neural cell adhesion molecule  
Neural cell adhesion molecule (NCAM) belongs to a family of adhesion molecules functioning 
in embryogenesis, cell growth and differentiation. The data for NCAM in the literature is 
inconsistently associated with perineural growth. In rectal cancer, NCAM is significantly 
associated with PNI.(68) Similarly, in one study of ACC, NCAM was highly expressed in 100% 
of tumours, regardless of PNI status. However, given the neurotropism ACC displays this is 
not an insignificant finding.(69) In another study (n=49), perineural invasion was more common 
in positive NCAM staining tissue.(70) The earliest cSCC study by Chen-Tsai et al (2004) was 
inconclusive, with 75% of cSCC expressing no NCAM at all.(64) A later study by Solares et al 
(2009) performed immunostaining, with an anti-CD56 antibody, in 14 cSCCHN with clinical 
PNI, 14 tumours without PNI and 4 normal nerves.(71) The authors found there to be no NCAM 
expression in any cSCCHN specimens, despite being strongly expressed in normal nerve tissue, 
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concluding no correlation of NCAM expression with perineural invasion in cSCCHN.(71) Other 
studies by Vural et al (2000) and McLaughlin et al (1999) did not differentiate between 
incidental and clinical PNI in demonstrating the converse finding.(72,73)  
 
2.6.4 Chemokines 
The directional nature of tumour cell perineural invasion makes chemotactic factors a logical 
avenue for investigation. A recent study showed that chemokine (C-C motif) ligand 2 
(CCL2/CCR2) signalling mediated prostate cancer cell migration and PNI in an in vitro 
model.(74) In this study a proteomic profiler chemokine assay was utilised to screen for secreted 
factors in the nerve microenvironment. Knockout studies for CCL2 demonstrated that CCR2 
activation facilitates perineural invasion. Furthermore, IHC revealed that 95% of prostate 
adenocarcinoma with PNI tissue specimens evaluated, exhibited CCR2 expression (n=20/21), 
supporting its potential as a future therapeutic target.(74) Another similar signalling pathway, 
chemokine (C-X3-C motif) ligand 1 (CX3CL1) binding CX3CR1 receptor, has demonstrated 
high expression in pancreatic and prostate cancers with PNI.(13,75) The CX3CR1 receptor is 
known to be heavily upregulated in malignant pancreatic epithelium. In binding its ligand, the 
transmembrane chemokine CX3CL1, which is expressed by neurons, exhibits intrinsic cell-
adhesive properties. Overexpression of CX3CR1 has been linked to metastasis in both prostate 
and breast cancer. Marchesi et al (2008) went on to demonstrate that high CX3XR1 expression 
was associated with perineural invasion, and subsequent risk of local recurrence in pancreatic 
cancer specimens.(75) In vitro, CX3CL1 promotes chemotaxis of pancreatic cancer cell lines 
and in vivo potentiates nerve infiltration of pancreatic tumours, revealing another potential drug 
target.(75) 
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2.6.4.1 Galanin 
A recent study by Scanlon et al (2015) rigorously investigated the role of galanin (GAL) in 
PNI and suggested the galanin receptor pathway as a novel therapeutic target for mucosal 
HNSCC with PNI.(44) The authors demonstrated that in HNSCC, galanin binds the GALR2 
receptor, which is one of three known G-protein coupled receptors for galanin. Downstream 
signalling was shown to induce neurogenesis in adjacent nerves, thus facilitating PNI.(44) Using 
the novel in vivo CAM model discussed earlier, they were able to elegantly demonstrate the 
reciprocity of interactions at the nerve-tumour interface, as first described by Ayala et al (2001) 
with their prototypical in vitro DRG-Matrigel model of PNI.(45) 
 
2.6.5 Ephrin/Eph receptor family  
 
The erythropoietin-producing hepatocellular carcinoma (Eph) receptor family comprises 14 
membrane-bound receptor tyrosine kinases (RTKs) in two receptor classes, class A and class 
B.(76) There are nine EphA (EphA1-8, Eph10) and five EphB (EphB1-4, EphB6) receptors that 
have been identified in humans.(77) These selectively interact with Eph receptor interacting 
proteins (ephrins) on neighbouring cell surfaces (Figure 8). Ephrins are named for their 
selective binding to either the A or B subfamilies, with EphA receptors binding ephrin-A 
ligands and EphB receptors binding ephrin-B ligands with high specificity. Notable exceptions 
are the EphA4 receptor, which can bind both ephrin A and B ligands, the EphB2 receptor, 
which can bind ephrin-A5 ligand, and the EphB4 receptor, which binds ephrin-B2 ligand 
exclusively. As both ligands and receptors are predominantly membrane-bound, Eph/ephrin 
interactions occur at sites of cell-cell contact or in plasma membrane clusters. Ligand binding 
triggers bidirectional kinase-dependent cytosolic signalling cascades.(78) Receptor-expressing 
cells undergo tyrosine kinase dependent forward signalling while reverse signalling occurs via 
Src family kinases in ephrin-ligand expressing cells.(78) Like other receptor tyrosine kinases, 
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on ligand binding, Eph receptors dimerise and undergo auto-phosphorylation with subsequent 
kinase activity. There are multiple downstream signalling effector pathways.   
 
 
Figure 8 Eph receptors and ephrin ligand interactions of A and B classes involve 
bidirectional signalling. Ephrin binding induces Eph receptor clustering, autophosphorylation and 
downstream forward signalling. Transmembrane ephrin-B ligands and glycosylphosphatidylinositol 
(GPI)-linked ephrin-A ligands mediate reverse signalling upon binding to their respective membrane 
bound Eph receptors. Figure from Pasquale et al (2010).(78)  
 
Eph/ephrin interactions have critical roles in developmental processes and normal adult 
physiology.(78) They are involved in regulating adhesion and migration at a cellular level, 
largely by modulating integrin signalling and binding of the ECM components laminin, 
collagen and fibronectin.(79) They have particularly important roles in neurodevelopmental 
processes, including axon guidance and neuronal circuitry.(80) They are also known to be 
important in normal human skin homeostasis, where EphA1, EphB3 and ephrin-A3 are 
expressed at high levels compared to other adult tissues.(77,81)    
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The Eph receptors/ephrins have also been implicated in tumourigenesis, progression and 
metastasis across a wide range of malignancies (Table 3).(82) However, their activities are 
evidently complex with both increased and decreased Eph receptor expression associated with 
cancer progression on review of the literature.(76)  Mutations in Eph receptors are also likely to 
have a role in tumour development and progression. Eph receptors and ephrins are commonly 
expressed not only in cancer cells but also in the tumour microenvironment.(78) They potentially 
facilitate abnormal cell-cell communication between tumour compartments.(78)  
 
Table 3 Erythropoietin-producing hepatocellular (Eph) receptor expression in various cancer types  
Expression Eph receptor Cancer type  
Upregulated EphA2 Adenoid cystic carcinoma(83) 
Prostate cancer(84,85) 
Breast cancer(86,87) 
Melanoma(88) 
Glioblastoma(89,90) 
Gastric cancer(91) 
EphA3 Gastric cancer(92) 
Colorectal cancer(93) 
EphB2 Advanced cSCC(94) 
Glioblastoma(95-97) 
Cervical cancer(98)  
Breast cancer(99) 
EphB4 HNSCC(100) 
Non-small cell lung cancer(101) 
Breast cancer(99) 
Downregulated 
 
 
EphA1 NMSC(77)  
EphA2 Chemically induced murine SCC(102) 
EphA3 Renal clear-cell carcinoma(103) 
EphB2 Prostate cancer(104) 
Colorectal cancer(105,106) 
Gastric cancer(107) 
Transitional cell carcinoma(108) 
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Both EphA2 and EphB4 are seen to be upregulated in a wide range of cancers.(109) EphB4 was 
shown to be highly expressed in the majority of HNSCC tumours evaluated in a study by 
Ferguson et al (2014).(100) Conversely, the EphA1 receptor is downregulated in advanced cSCC 
and along with the EphB receptors is also downregulated in advanced colorectal cancer.(77,105) 
Notably, significant EphA1 downregulation was observed by Hafner et al (2006) in a study of 
32 cutaneous SCCs compared to normal epidermis and appeared to correlate with tumour 
thickness.(77) With respect to the tumour microenvironment, both ephrinA1/EphA2 and 
ephrinB2/EphB4 signalling has been characterised in tumour vasculature.(78)  
 
Moreover, EphB2 was shown to be overexpressed in human cSCC compared to premalignant 
lesions and normal skin in a study by Farschian et al (2015).(110) Knockdown of EphB2 
signalling resulted in down-regulation of genes associated with cell invasion, including matrix 
metalloproteinases MMP1 and MMP13, and inhibited progression and invasion of human SCC 
cell lines. This is early evidence of the role of EphB2 in aggressive advanced cSCC and 
suggests a possible therapeutic target. EphB2 may well be over-expressed in the subset of 
advanced cSCC with perineural spread and certainly warrants further investigation in this sub-
population. 
 
A study by Shao et al (2013) recently implicated EphA2/ephrinA1 in adenoid cystic carcinoma 
of the salivary gland.(83) Increased levels of mRNA and expression of product proteins EphA2 
and ephrinA1 was seen in ACC tissue compared to normal gland tissue by 
immunoprecipitation, PCR and IHC. This correlated with clinical tumour-node-metastasis 
(TNM) staging, vascular invasion and perineural invasion. In one instance, nerve invaded by 
ACC cells showed ephrinA1 staining with weak EphA2 staining also observed. Together, these 
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findings suggest a possible role of EphA2/ephrinA1 interactions in perineural invasion of 
ACC.(83)    
 
The Eph/ephrin signalling pathway is a current research focus in the development of targeted 
therapies to either interfere with tumour promotion or enhance tumour suppressor effects.(78) It 
is also becoming clear that Eph/ephrin signalling may play a role in resistance to anti-cancer 
therapies. In breast cancer tumour xenograft studies, EphA2 expression is associated with 
resistance to tamoxifen (anti-oestrogen receptor antibody) and Herceptin (anti-HER2 receptor 
antibody).(111) Several clinical trials with anti-Eph receptor agents are currently underway, 
including an EphA2 inhibitor (Dasatinib) in various solid tumours and an anti-EphB4 agent 
(XL647) in non-small cell lung cancer (NSCLC).(111)  
 
Little is known about Eph/ephrin expression in the perineural compartment or tumour cells 
invading the perineural space. Invasion of tumour cells and subsequent spread along the 
perineural space is probably cell-cell contact dependent. Interestingly, EphB/ephrinB, 
particularly EphB1/ephrinB2, interactions have also been implicated in neuropathic pain 
caused by cancer, inflammation and nerve injury.(112) In a rodent model, EphB receptor 
inhibition has been shown to alleviate neuropathic pain.(112)  
 
Given the demonstrated importance in neurodevelopmental processes, normal skin physiology, 
the balance between tumour suppression and tumour progression and neuropathic pain, the 
Eph/ephrin pathway is a candidate signalling axis for investigation in perineural invasion and 
spread of cSCCHN. Certainly, there is a gap in knowledge regarding this family of RTKs in 
perineural spread of carcinoma. Dysregulation of cell-surface ligand/receptor expression in 
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tumour cells and/or the nerve-tumour microenvironment may potentially facilitate infiltration 
of the perineural space and subsequent progression. 
 
2.6.6 ErbB receptor family 
The ErbB family is a group of homologous transmembrane RTKs comprising EGFR (HER1, 
ErbB1), HER2 (ErbB2), HER3 (ErbB3) and HER4 (ErbB4). Each receptor has an extracellular 
ligand-binding domain, a transmembrane region and an intracellular cytoplasmic domain 
which includes a tyrosine kinase residue (Figure 9).(113) These receptors are activated by growth 
factors such as the epidermal growth factor (EGF) and related ligands. Receptor activation by 
ligand binding leads to homo- or heterodimerisation and trans-phosphorylation of 
corresponding tyrosine kinase domains. This leads to activation of well characterized 
intracellular signaling pathways involved in cell proliferation, survival, differentiation and 
migration (Figure 9).(113)  
 
EGFR is the prototypical RTK and is activated by its ligand EGF and other closely related 
growth ligands. HER2 has a non-functional ligand binding domain and thus exists in a 
constitutively activated conformation, making it the preferred dimerization partner for other 
receptors.(114) HER3 has a kinase domain dependent on phosphorylation with another ErbB 
receptor and is thus considered an impaired RTK.(114) 
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Figure 9 Downstream signaling pathways of activated ErbB receptor tyrosine kinases. 
Stimulatory (open) and regulatory (closed) arrows are shown. Mitogen-activated protein kinase 
(MEK), extracellular signal-regulated kinase (ERK), tuberous sclerosis complex 2 (TSC2), 
mechanistic target of rapamycin (mTOR), PH domain and leucine rich repeat protein phosphatases 
(PHLPP), Ptdlns(3,4,5)P3-dependent protein kinase (PDKI), SH2-containing inositol phosphatase 
(SHIP), phosphatase and tensin homolog (PTEN), son of sevenless (SOS), guanosine triphosphate 
(GTP), guanosine diphosphate (GDP), growth factor receptor-bound protein 2 (GRB2), GTPase-
activating protein (GAP). Figure from Sharma et al (2007).(115) 
  
Downstream signaling pathways include the phosphatidylinositol 3-kinase (PI3K)/Akt 
pathway and the Ras/Raf/MEK/MAPK (mitogen activated protein kinases) pathway.(116) 
Ligand-induced activation leads to clustering of the receptors into clathrin coated pits which 
invaginate to form vesicles, a process catalyzed by dynamin, a large GTPase.(117) Thus, 
dynamin mediates internalization of activated ErbB receptor complexes to the early endosome, 
where receptors are either recycled back to the cell surface or proceed to lysosomal 
degradation. Contrary to previous understanding, activation of intracellular signaling pathways 
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occurs from both the plasma membrane and the endocytic compartment with qualitative 
differences in signaling recently described.(118) Thus, receptor trafficking is now recognised to 
be important in modulating downstream signaling.  
 
The dysregulation of ErbB receptor trafficking is associated with tumorigenesis and tumour 
progression across various malignancies. Some mechanisms well characterized in different 
tumour types include receptor over-expression and activating mutations in receptors leading to 
aberrant tyrosine kinase signaling.(113) Overexpression of EGFR is commonly seen in HNSCC, 
NSCLC and colorectal cancer (CRC) and is most often secondary to gene amplification and 
results in prolonged signaling even with low ligand concentrations. HER2 overexpression is 
commonly observed in breast and gastric cancers.(119) One other mechanism by which ErbB 
receptors potentiate cancer is through activating mutations which allow escape from normal 
regulation. The EGFRvIII mutation leads to a truncated receptor lacking a functional ligand 
binding domain.(115) Effects are twofold, the receptor is constitutively phosphorylated leading 
to constant activation of MAPK and PI3K/Akt pathways and secondly there is no catalyst for 
internalization allowing prolonged signaling. This mutation is commonly seen in NSCLC but 
is not significant in mucosal HNSCC.    
 
2.6.6.1 EGFR expression in cSCCHN  
EGFR overexpression is documented in approximately one third of epithelial malignancies 
across head and neck, colorectal, breast, ovarian, prostate, bladder and lung cancers.(120) In 
cutaneous SCC, EGFR over-expression is reported in approximately 35% of primary cSCC 
and up to 58% of advanced local cSCC or nodal metastatic disease (Table 4). To our 
knowledge, no previous study has examined EGFR expression in perineural spread of 
cSCCHN at the protein level. In unpublished data from our own laboratory, 48% of cutaneous 
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SCC (n = 58/120) were EGFR over-expressing using secondary immunofluorescence 
techniques (verbal communication, Dr Fiona Simpson, 2016). Perineural spread is an advanced 
subset of cSCCHN and of note from the literature it is apparent that as disease stage for cSCC 
increases, positivity for EGFR also increases. Regardless, there is a significant gap in our 
understanding of EGFR and other ErbB receptor expression in perineural spread cSCCHN.  
 
Table 4 EGFR positivity reported in primary and nodal metastatic cSCCHN  
 
 
2.6.6.2 Targeted therapies to the ErbB family  
It is unsurprising that the ErbB receptor family has been the focus of novel cancer therapeutic 
development for some years. Strategies have included immunotherapy using monoclonal 
antibody therapies (mAbs) which target the patient immune system against tumour cell specific 
antigens. Small-molecule tyrosine kinase inhibitors (TKIs) have also been developed and are 
approved in several malignancies (Figure 10).  
 
There are four FDA-approved therapeutic mAbs available in the clinic including both anti-
EGFR (cetuximab, panitumumab) and anti-HER2 (trastuzumab, pertuzumab) drugs. 
Trastuzumab (Herceptin) was the first to be approved for use in HER2 positive metastatic 
breast cancer and is now also used in high-risk non-metastatic HER2 positive tumours.(121) 
More recently it was approved for HER2 positive metastatic gastric or gastroesophageal 
junction cancer.(121) A benefit in patients has only been shown where tumours are demonstrably 
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HER2 positive. HER2 positive status is associated with aggressive disease and worse patient 
outcomes in breast and gastric cancer. Trastuzumab is thought to inhibit downstream signaling, 
induce antibody-dependent cell cytotoxicity (ADCC) and reduce receptor shedding.(122) It also 
has been shown to work synergistically with some chemotherapy regimens.  
 
Cetuximab (Erbitux) was the first anti-EGFR therapy to reach the market in 2004 as an 
approved treatment for metastatic colorectal cancer patients with EGFR positive tumours, as a 
single agent or in combination with chemotherapy.(123) Patients with KRAS mutant tumours or 
an unknown gene status are not treated with cetuximab, as several sub-group analyses have 
shown a survival disadvantage in this group.(123) It is also now approved as a first line therapy 
for locally or regionally advanced HNSCC in combination with radiotherapy, for recurrent or 
metastatic HNSCC in combination with chemotherapy or in disease progression on standard 
platinum based regimens.(124) 
  
 
Figure 10 Targeted therapies against the ErbB receptor family. Anti-EGFR monoclonal 
antibody therapies include cetuximab and panitumumab and anti-HER2 monoclonal antibodies include 
trastuzumab and pertuzumab. Gefitinib and erlotinib are small molecule tyrosine kinase inhibitors 
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which act on the intracellular domain of EGFR, while lapatinib acts on both the EGFR and HER2 
receptors to inhibit receptor tyrosine kinase signaling. Everolimus is an inhibitor of mammalian target 
of rapamycin (mTOR). Figure from Okines et al (2011).(125) 
 
Anti-cancer immunotherapy is now understood to work both directly and indirectly; directly 
by inhibiting downstream cell signaling and indirectly by inducing antibody-dependent cell 
cytotoxicity (ADCC).(126) For example, the chimeric IgG1 cetuximab, through high affinity 
binding to EGFR, prevents true ligand binding and receptor dimerization, thus inhibiting 
downstream signaling. Such binding also promotes receptor internalization. Moreover, by 
binding FcγRIII on natural killer (NK) cells, cetuximab induces ADCC.(127) Classical ADCC 
involves activation of NK cells, most commonly via their cell surface Fc receptor CD16, also 
known as FcγRIII, which binds the Fc region of IgG coating the tumour cell, resulting in 
tumour cell lysis. This has been shown to be an important mechanism of action for Cetuximab 
and several other therapeutic monoclonal antibodies. Trastuzumab has similar actions in that it 
binds the extracellular domain of ErbB2 preventing dimerization with other ErbB receptors 
and promotes downregulation via endocytosis. It also induces ADCC via the FcγRIII receptor 
on NK cells.(128)   
 
Given the proven role of ErbB receptors in cancers at various sites, including head and neck 
and cutaneous carcinomas, we postulate a possible role in perineural spread of carcinoma. To 
our knowledge there has been no study to date examining the role of receptor tyrosine kinases, 
including the ErbB and Eph receptor families, in perineural spread of cSCCHN.     
 
2.6.7 Genetic profile of cSCCHN with and without PNS 
With the advent of next generation sequencing technology, genetic profiling of many cancers 
has been undertaken. In cSCC there is a massive mutational burden, making identification of 
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driver genes difficult and translation from genomics to the clinical setting slow.(129-131) There 
has been significant work looking at progression of AK to cSCC and recognition that like other 
malignancies, this is a multi-hit process requiring several accumulated genetic and epigenetic 
alterations in key pathways to culminate in invasive SCC.  
 
The majority of published research in genomic studies of cSCC has revealed and focused on 
mutations in tumour protein 53 (TP53), NOTCH, RAS, EGFR, SRC-family kinase (SFK), 
cyclin-dependent kinase inhibitor 2A (CDKN2A), NFκβ and transforming growth factor beta 
(TGF-β).(132) One of the major recognised cellular drivers of SCC is loss of function of the 
tumour suppressor gene TP53. Data supports a strong correlation between solar ultraviolet 
radiation (UVR) and mutational burden in the p53 gene with up to 90% of squamous cell 
carcinomas exhibiting p53 mutations.(131,133,134) It is thought that UV radiation has direct effects 
at the TP53 locus with mutations affecting cell cycle regulation and allowing clonal expansion 
to occur.(134,135) Members of the mitogen activated protein kinase (MAPK) family are also 
thought to play a significant role in in cSCC.(136)   
 
The EGFR has also been implicated in the carcinogenesis of cSCC at the genetic level. EGFR 
is known to be constitutively activated in a subset of invasive cSCC and is an important 
emerging drug target.(133) Homo- or heterodimerisation induced by ligand binding or directly 
by UVR results in auto phosphorylation of the intracellular tyrosine kinase, activating 
downstream signalling and promoting cell proliferation, migration, survival and suppression 
of differentiation.(135) On the other hand, mutations in the EGFR are not known to play an 
important role in the carcinogenesis or progression of cSCC, as they are at some other sites.    
 
51 
 
In a recent mutational analysis, Pickering et al (2014) identified 23 candidate driver gene 
mutations after whole genome sequencing of 39 cases of advanced cSCC.(132) The authors 
concluded that the mutational signature of advanced cSCC is similar to mucosal HNSCC and 
dominated by tumour suppressor genes, with 8 of the top mutated genes shared between these 
tumour types. Similarly, an earlier study by Dooley et al (2003) found genetic profiles between 
oral SCC cell lines and facial cutaneous SCC cell lines to be highly similar across 23 
biomarkers.(137) NOTCH1 and NOTCH2 were both significantly mutated with NOTCH2 
positively associated with PNI in this study.(137)  
 
More recently, Li et al (2015) undertook genomic analysis of 29 cases of nodal metastatic 
cSCC, performing targeted sequencing of 504 cancer-associated genes.(138) The authors 
focused on identifying clinically significant genomic alterations and found 
phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha (PIK3CA), fibroblast 
growth factor receptor 3 (FGFR3), BRAF and EGFR to be potential therapeutic targets.(138) 
Although informative for our study, nodal metastasis and perineural disease are not inherently 
related, with only 5.8% of patients with perineural spread presenting with concomitant nodal 
disease at our institution.(22) While perineural spread is a form of tumour metastasis, we 
consider it to be distinct from haematogenous or lymphatic dissemination with similarly 
distinct molecular profile. However, both forms of tumour spread represent aggressive forms 
of the same underlying malignancy and it is important to consider significant alterations in the 
nodal metastatic cohort. Interestingly, EphA7 and EphA3/4 were significantly over-expressed 
in nodal metastatic cSCC in 27% and 20% of specimens, respectively. EphA1, EphA2 and 
EphB1 were less commonly overexpressed with an incidence of 10% overexpression reported 
for each receptor.(138)    
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Comparable results were seen in more recent genomic profiling by Al-Rohil et al (2016) of 122 
cSCC cases looking at both primary (63%) and metastatic (37%) lesions.(139) Across these 
samples they identified a total of 1120 genomic alterations with 88% of cSCCs harbouring at 
least one clinically relevant genomic alteration (CRGA) for which there is an anticancer drug 
already on the market or in clinical trial. The most common CRGA was in NOTCH1 (43%) 
with PTCH, ATM, ErbB4 (HER4), NF1, ErbB2 (HER2), PIK3CA, CCND1, EGFR and 
FBXW7 over-expression recorded in 5-11% of specimens for each marker.(140) 
 
To date, there have been very few gene-profiling studies to identify driver genes involved in 
perineural invasion or spread. Using microarray expression analysis to analyse more than 
20,000 genes, Mays et al (2015) identified 24 differentially expressed genes between 
specimens of cSCC with and without microscopic PNI, none of which before had been 
implicated in perineural disease.(141) However, unfortunately they were unable to identify any 
biological pathways associated with these differentially expressed genes by gene ontology 
enrichment analysis. The authors did highlight the possible role of down-regulation of the 
tumour suppressor gene TXNIP in aggressive PNI, given a > 2-fold reduction was observed in 
PNI positive specimens. However, this reinforces the necessity and value in focusing on 
clinically relevant and druggable biomarkers and pathways.    
 
Our collaborators at the Queensland Institute of Medial Research (QIMR) have undertaken 
whole genome expression profiling of cSCCHN without PNI versus microscopic PNI versus 
clinical PNS.(142) This study identified a wide range of genes that were differentially up or 
downregulated across the groups. Several statistically and biologically significant differentials 
were identified, including downregulation of transglutaminase 3 (TGM3) and up-regulation of 
lysyl oxidase like 2 (LOXL2) and EphA3 in the perineural spread cohort (Figure 11). TGM3 
53 
 
and LOXL2 were selected for further study in the subcutaneous mouse model, however due to 
small numbers and variable tumour growth no significant conclusions could be drawn.(51,142) 
Generous provision of the raw microarray data allowed differential expression levels of Eph 
receptors and ephrin ligands to be specifically reviewed as part of this thesis (Table 5). In 
addition to up-regulation of EphA3, EphA4 and EphA5 were elevated without reaching 
statistical significance. Downregulation of EphA1 as well as EphB1 and EphB6 was also 
observed in perineural spread cSCCHN compared to control cSCCHN.  
 
Figure 11 Main target genes identified as downregulated (left panel) or upregulated (right 
panel) in perineural spread cSCCHN compared to cSCCHN without perineural invasion. Gene 
microarray analysis  was performed at QIMR Berghofer by Dr Glen Boyle in collaboration with Prof 
Ben Panizza, who generously provided this image.(142) Function of each gene is briefly described. Ca, 
cancer; HNSCC, head and neck squamous cell carcinoma.  
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Table 5 Data extracted from gene microarray analysis of cSCCHN with and without perineural spread 
for ephrin ligand/Eph receptor gene expression.  
 
 
 
 
 
 
*Indicates statistically significant differential gene expression, defined as > 3-fold absolute fold change  
and p-value < 0.01 (Mann-Whitney).   
 
Subsequent pathway analysis by our collaborators revealed genetic signatures representative 
of activation of the p53 pathway in cSCCHN with perineural spread compared to cSCCHN 
without perineural involvement.(142) The authors proceeded to examination of p53 at the protein 
level by immunohistochemistry, which revealed an absence of normal p53 staining in all 
tumours with PNS and a preponderance of a diffuse over-expression pattern. Although this did 
not correlate with a difference in p53 mutation number or position there was a significant 
differential observed in regulators of p53 stability, activity and degradation consistent with 
dysregulation of the p53 pathway in cSCCHN with perineural spread.(142)   
 
2.6.8 Other molecular biomarkers 
Aside from this single study looking at genetic alterations in perineural spread cSCCHN there 
is a paucity of data on the expression profile of important cancer biomarkers in perineural 
spread cSCCHN. The p53 pathway clearly warrants further investigation in perineural spread, 
building on the earlier work of our colleagues.(142) p16 is another well recognised cell cycle 
regulator that is implicated in carcinogenesis and tumour progression that has not previously 
Gene Regulation Absolute FC P-value (Mann-Whitney) 
EphA3 Up* 6.31 0.001 
EphA5 Up 1.80 0.001 
EphA4 Up 1.02 0.013 
EphB6 Down* 4.28 0.004 
EphA1 Down* 3.92 0.001 
EphB1 Down* 3.59 0.009 
EFNB3 Down 2.70 0.019 
EFNB1 Down 2.61 0.017 
EFNB2 Down 1.93 0.007 
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been examined in perineural spread cSCCHN. It is also widely used as a surrogate marker of 
high risk human papilloma virus (HPV) infection in the cervix and oropharynx. Ki-67 is 
histopathological marker of cellular proliferation with the calculated proliferation index (PI) 
often correlating with clinical disease course in carcinomas. It is an emerging biomarker for 
tumour stratification and prognostication, particularly in breast cancer. Despite potentially 
important implications, to our knowledge no previous studies have examined the expression 
profiles of these biomarkers in perineural spread of cSCCHN.  
 
2.6.8.1 p53 pathway 
The TP53 gene is the most frequently mutated gene in human cancer. It has been labelled the 
“guardian of the genome” and is the prototypical tumour suppressor gene acting through 
various anti-cancer mechanisms, including activation of DNA repair apparatus, arrest of the 
cell cycle and initiation of apoptosis in the setting of irreparable genetic damage.(143,144) Many 
studies have investigated the significance of TP53 mutations in the prognosis and treatment of 
tumours at various sites. Mutations in cutaneous carcinoma occur early and often with no 
definite prognostic correlation in the literature.(145) The presence of a TP53 mutation is known 
to confer poor prognosis in colorectal, lung, prostate, and breast cancer.(144) At other sites, 
genetic alterations have been associated with treatment resistance. Given the significant labour 
and time cost involved in nucleotide sequencing, p53 IHC has become a surrogate marker 
utilised in clinical and research laboratories.(146) This has been based on the premise that wild-
type p53 has a short half-life and is generally detectable only at low levels by IHC. Conversely, 
mutated p53 has a prolonged half-life and nuclear accumulation facilitates 
immunohistochemical detection. A consensus of studies regard strong and diffuse 
immunolabeling as abnormal and suggestive of a missense TP53 mutation while completely 
negative staining implies a non-immunoreactive truncated protein, likely secondary to a 
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nonsense mutation.(147) In the absence of a TP53 mutation a weak or focally positive 
immunoreaction is most commonly observed. In a study of ovarian carcinomas, combining the 
two immunohistochemical patterns associated with mutations correctly identified TP53 
mutations in almost all cases.(148) A similar study was undertaken in colorectal 
adenocarcinoma, where three distinct patterns of p53 protein expression were observed: 
complete negative immunostaining, restricted expression characterised by focal positive 
staining and diffuse over-expression characterised by diffuse strongly positive staining.(147) 
 
As discussed earlier, recent data published by our collaborators attempted to correlate 
immunohistochemical staining patterns of p53 expression in perineural of cSCCHN with 
mutational analysis data. The authors observed three distinct patterns as described by 
Nyiraneza et al (2011), and that compared to incidental PNI or tumours with no PNI, cSCCHN 
with PNS was significantly more likely to exhibit a strongly positive diffuse over-expression 
pattern.(147) Their study went on to suggest a probable role for the p53 pathway in the process 
of perineural spread. The results of the analysis showed signatures of gene expression 
representative of activation of p53 in tumours with PNI compared to tumours without, with 
regulators of p53 degradation, stability and activity significantly altered. Although at the gene 
loci analysed there was no difference in TP53 mutation or location, immunohistochemistry 
revealed a diffuse over-expression pattern or negative staining to be most common. We sought 
to build on this novel data by completing p53 immunohistochemistry in our cohort of perineural 
spread cSCCHN and pooling data for analysis. 
 
2.6.8.2 p16 tumour suppressor gene 
p16 is a cyclin-dependent kinase inhibitor encoded by the CDKN2A gene involved in 
regulation of the cell cycle.(149) This tumour suppressor gene is frequently mutated or deleted 
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in a wide range of cancers. The encoded p16Ink4a protein is activated during cell cycle 
progression upon the release of retinoblastoma protein (pRB) from the transcription factor E2F. 
The p16 protein is integral in the negative feedback loop which maintains the balance between 
cell proliferation and cell cycle arrest by inhibiting progression from G1 to S phases.(149) Up to 
50% of human malignancies show p16 inactivation or downregulation, including head and 
neck carcinomas.(149,150) Conversely, some tumour sub-types display significant p16 
overexpression which can be detected immunohistochemically. Most notably, HPV associated 
tumours have high rates of p16 over-expression such that p16 positivity is regarded as a 
surrogate marker for the presence of high-risk HPV genotypes.(149,151) For example, in the 
cervix, persistent high risk HPV infection leads to production of viral E6 and E7 oncoproteins 
that dysregulate the cell cycle by disrupting binding of pRB to E2F. This releases p16 from its 
negative feedback control leading to hyperproliferation and a paradoxical increase in p16 
expression.(149)   
 
p16 has been explored as a biomarker in several other cancers. HPV is responsible for an 
increasing percentage of oropharyngeal HNSCC, while not appearing to play an important role 
at other mucosal sites in the upper aerodigestive tract.(152,153) In recent clinical data from our 
institution, 79% of oropharyngeal SCC was p16 positive by immunohistochemistry (verbal 
communication, Ben Panizza, 2016). HPV related oropharyngeal SCC is highly radiosensitive 
and thus p16 over-expression confers a recognised prognostic benefit in this setting.(154) 
 
Non-HPV related p16 overexpression has been observed in other malignant tumours and has 
also been associated with transformation from pre-malignant lesions.(149) Overexpression in 
malignant tumours is thought to represent an attempt to arrest the uncontrolled proliferation 
secondary to failure of the Rb pathway. As alluded to earlier, escape from this regulatory 
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pathway can be secondary to viral infection, gene mutations or other yet uncharacterised 
mechanisms. Certainly, restoration of p16 tumour suppressor functionality remains a viable 
anti-cancer strategy under investigation at other sites. Moreover, regardless of the mechanism, 
p16 has demonstrated utility as an independent prognostic marker outside the head and neck. 
In colorectal adenocarcinomas and breast carcinomas, p16 over-expression in a subset of 
tumours has been repeatedly shown to correlate with unfavourable clinical features.(149)  
 
A proportion of cSCC are positive for p16 immunohistochemistry, however solar UVR can 
equally be responsible for mutation and dysregulation of expression of this cell cycle protein. 
Low risk HPV DNA has been detected in cSCC however there is not an increased prevalence 
of known high-risk sub-types.(155) It remains unclear whether chronic HPV infection plays a 
significant causal role in the carcinogenesis of cSCC or whether the virus is simply a bystander. 
In primary cSCC the role of p16 staining as a surrogate marker for HPV infection and/or as a 
prognostic factor is not clear. Hodges et al (2002) demonstrated increasing p16 expression in 
the progression from AK to CIS to SCC.(156) Later studies have shown that p16 status in cSCC 
does not correlate with the presence of HPV DNA and therefore, like most of the mutational 
burden, may be secondary to UV mediated DNA damage. However, in the setting of metastatic 
cervical nodal SCC of unknown origin, p16 immunohistochemistry is considered in many 
centres a useful adjunct in differentiating between an occult mucosal or occult cutaneous 
primary lesion.(157) There is recent literature looking at p16 expression in cervical lymph nodes 
of known cutaneous origin. A recent study by McDowell et al (2016) evaluated p16 
immunohistochemistry in 143 cSCCHN lymph node metastases to the parotid gland.(158) The 
authors performed HPV RNA in situ hybridisation (ISH) in a subset of 59 patients to detect 
high-risk HPV sub-types. Of the cohort, 31% had positive and 15% weak p16 expression, with 
54% exhibiting no staining. Overall and disease-free survival were not correlated with p16 
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status.  Equally, there was no correlation of p16 status with high-risk HPV sub-type. Another 
study by Beadle et al (2013) found p16 expression to be relatively common in lymph node-
positive cutaneous head and neck SCC and similarly recommended against use of p16 as an 
independent indicator of an occult oropharyngeal primary.(159) An earlier study by Compton et 
al (2011) evaluated HPV status using both fluorescence in situ hybridisation (FISH) and p16 
status, reporting 28% of metastatic lymph nodes from occult primary tumours to be HPV 
positive.(160) There remains a paucity of data and no systematic review has been performed to 
date. 
 
To our knowledge, p16Ink4a expression has not previously been examined in cSCCHN with 
PNS. We hypothesise that viral or UVR associated dysregulation of the p16 pathway may be a 
contributing driver for perineural invasion. The hypothesis that chronic viral infection, either 
with HPV subtypes or other viruses, may predispose to or facilitate perineural invasion and/or 
spread is novel although plausible. Infection and associated inflammation may affect the 
integrity of the perineural sheath and space. A subset of HPV-associated mucosal HNSCC 
tumours have a significant inflammatory infiltrate compared to HPV negative tumours.(161,162) 
A recent study by our collaborators has similarly demonstrated the presence of a significant 
inflammatory infiltrate in the setting of perineural spread cSCCHN.(43) Potentially chronic HPV 
infection and an increased inflammatory infiltrate associated with certain cutaneous SCCs 
might explain at least some of the tendency for particular tumours to undergo perineural 
invasion and spread. A pathogenic role for neurotropic viruses, such as the human 
herpesviruses, has also not been considered previously but is beyond the scope of our current 
study and certainly an avenue for future research. Regardless of the putative underlying 
mechanism, defining the expression profile of p16 in perineural spread cSCCHN may assist 
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our understanding of the disease process or with further clinical correlation reveal a novel 
prognostic factor.  
 
2.6.8.3 Ki-67 proliferation index 
The Ki-67 antigen is a non-histone nuclear protein involved in the early steps of RNA 
synthesis.(163) Its exact role remains uncharacterised however appears important in cell 
division, with expression varying through the phases of the cell cycle. It is not expressed during 
the resting G0 phase but is expressed during replication, peaking at mitosis. The MIB-1 
antibody can be used to detect the Ki-67 antigen on formalin fixed paraffin embedded (FFPE) 
tissue sections and calculate the percentage of cells with strong nuclear positivity and thus 
actively undergoing mitosis.(164) This Ki-67 score is known as the proliferation index (PI) and 
has been evaluated across a range of malignancies as a marker for aggressive disease and poor 
clinical outcome. The utility of Ki-67 as a biomarker in breast cancer has been most extensively 
investigated, with a proliferation index > 10-14% conferring higher risk.(165) Per consensus 
guidelines published in 2009, Ki-67 score is used to classify tumours as low (<15%), 
intermediate (15-30%) or highly (>30%) proliferative.(166) It is this and other biomarkers in 
breast cancer that determine whether multi-drug therapy is indicated. A high PI has also been 
correlated with survival outcomes in prostate, brain and neuroendocrine tumours.(167,168) 
 
Limited studies have looked at proliferation index in cSCC. On the spectrum of actinic 
keratosis to carcinoma in situ (CIS) to invasive SCC, proliferation index has been shown to 
increase.(169) In one recent study, all cases of cSCC were positive for Ki-67 expression with a 
mean PI of 85%.(169) Another study which evaluated Ki-67, p53 and p16 in 10 cases of invasive 
SCC, showed one case to have a PI > 30% while three cases had a PI 5-30% and the remaining 
six cases had PI < 5%.(170) No previous studies have investigated this biomarker in perineural 
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spread of cSCCHN, likely because it has not previously been considered a highly proliferative 
process. However, without data on mitotic rate or Ki-67 index this remains supposition. The 
paradigm to date has very much focused on tumour cells traversing the space in a directional 
manner rather than simply proliferating within the perineural compartment. Although many 
cases present with slowly progressive clinical disease, other cases are rapidly progressive 
towards the brain stem or can be locally aggressive as in the setting of peripheral recurrence. 
There is in vitro data reporting proliferation index in the DRG-tumour co-culture model, where 
it was shown that neurites induce proliferation of SCC cell lines.(46) It is a logical extension to 
address this evident gap in the literature by examining Ki-67 expression in tissue sections of 
cSCCHN with PNS and correlating the proliferation index with existing clinicopathological 
factors and other potential biomarkers of interest. 
 
3.0 Clinical significance and rationale  
 
The molecular mechanisms underlying perineural spread of cSCCHN are poorly understood 
and there has thus been no advances in development of targeted therapy. Adequate oncologic 
resection and adjuvant radiation therapy can add significant morbidity to an already morbid, 
and if left untreated, ultimately fatal, disease process. The lack of clinically relevant biomarkers 
limits our ability to risk stratify and prognosticate patients and de-intensify therapy when 
appropriate.   
 
Immunotherapy is the current frontier in cancer treatment. Therapeutic antibodies have the 
advantage of blocking the transduction of pro-tumour signalling and localizing and amplifying 
the host immune response to tumour. A range of therapeutic antibodies are in clinical use or 
under development for a variety of malignancies. These antibodies, most frequently of the IgG 
class, bind their specific antigen or receptor molecule, thus interfering with cell signal 
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transduction and the processes of cell growth, migration and proliferation. It is now well 
understood that anti-tumour effects are also a function of the antibody Fc domain mediated 
induction of effector functions, which can include complement-dependent cytotoxicity (CDC), 
antibody-dependent cell-mediated cytotoxicity (ADCC) and antibody-dependent 
phagocytosis.(124) Antibodies also provide an opportunity to target other anti-tumour 
treatments, such as radiation, drugs and toxins, to tumour cells through conjugation. Locating 
druggable antigens that are largely tumour specific or selective allows such targeted therapy to 
occur while minimising harmful side effects. 
 
The balance of RTK activity plays a critical role in tumorigenesis, progression and metastasis 
in a variety of cancers. We hypothesise that one or more of these membrane receptors is 
implicated in the perineural spread of carcinoma. If so, the availability of existing monoclonal 
antibody therapies would make for a readily exploitable target. The EGFR is an established 
therapeutic target in breast, colon and head and neck cancers with use of the chimeric IgG1 
antibody cetuximab. Similarly, panitumumab is a humanised anti-EGFR monoclonal antibody 
approved in pancreatic and colorectal cancer.(124) Trastuzumab is a humanised IgG1 targeting 
the HER2 receptor approved in breast and now gastric and gastro-oesophageal cancer. Further 
highly specific monovalent and multivalent antibodies targeting Eph receptors and other 
members of the ErbB family are in development and clinical trial.  
 
To our knowledge this is the first study to examine the role of RTKs in the molecular 
mechanisms underlying perineural invasion and spread in cSCCHN. In applying 
immunohistochemistry and immunofluorescence techniques and high-resolution imaging we 
hope to identify markers and pathways associated with perineural spread to shed light on 
therapeutic targets. Moreover, this is the first body of work to examine the expression profile 
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of well-recognised cancer biomarkers, including the cell cycle regulators p16 and p53, and the 
proliferation marker Ki-67, in perineural spread cSCCHN. Specifically this work builds on 
gene expression analysis and recently published data suggesting aberration of the p53 pathway 
in perineural spread.(142) Findings may have implications for treatment and prognostication of 
advanced cSCCHN with PNI as well as other neurotropic malignancy, including pancreatic, 
gastric, colorectal and prostate cancers. Specific treatment of perineural invasion and spread 
would improve patient survival and quality of life.   
 
4.0 Hypothesis 
Study of the pattern of expression and cellular localisation of receptor tyrosine kinases 
and other cancer biomarkers will contribute to understanding the molecular mechanisms 
underlying perineural spread of carcinoma. We hypothesise that dysregulation of receptor 
tyrosine kinase trafficking plays a role in perineural spread cSCCHN as in other forms of 
squamous cell carcinoma. Identification of such proteins may allow re-purposing and/or novel 
development of targeted therapies including immunotherapy. Correlation of biomarkers with 
clinical factors may allow patient prognostication and rationalisation of therapy in the future.   
 
5.0 Aims 
1. To define the level and cellular distribution of Eph and ErbB receptor tyrosine 
kinases on SCC cell lines; and 
2. To define the level and cellular distribution of Eph receptors and ErbB receptors in 
human tissue specimens of perineural spread cSCCHN; and  
3. To determine the expression profile of the proliferation marker Ki-67 and cell cycle 
regulators p53 and p16 in perineural spread cSCCHN  
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6.0 Materials and methods  
6.1 Antibodies  
Primary antibodies used in this study are tabulated below with concentrations used for various 
applications (Table 6). Commercial primary and secondary antibodies were purchased from 
sources as indicated. Pre-dilute clinically approved antibodies for immunohistochemistry for 
HER2, Ki-67 and p16Ink4a were used as per manufacturer protocols on automated platforms. 
HRP conjugated secondary antibodies for Western blot were diluted to 1/10,000. Alexa 
FluorTM fluorophore conjugated secondary antibodies for cell and tissue immunofluorescence 
experiments were diluted to 1/200. The Ventana Discovery anti-HQ HRP detection system was 
used for immunohistochemistry performed on the Ventana Discovery Ultra platform (Ventana 
Medical Systems, Inc. USA) at the Translational Research Institute Core Histology Facility.  
 
Table 6 Antibodies used in experimental work  
Antibody Clone Source IgG WB 
Conc. 
Cell 
IF 
Conc. 
Tissue 
IHC/IF 
Conc. 
Optimised 
retrieval/incubation 
conditions and time   
β-tubulin 2-28-33 Invitrogen Mouse 1/10,000 n/a n/a n/a 
EphA2 D4A2 CST Rabbit 1/1000 1/200 Serial 
dilutions* 
n/a 
EphA3 L-18 
polyclonal 
Santa Cruz Rabbit 1/200 1/50 n/a n/a 
EphB1 Q-20 
polyclonal 
Santa Cruz Rabbit 1/1000 1/50 n/a n/a 
EphB2 AF467 R&D  Goat 1/500 1/20 Serial 
dilutions* 
n/a 
EphB4 D1C7N CST Rabbit 1/1000 1/640 Serial 
dilutions* 
n/a 
S100 Z0311 DAKO Rabbit n/a n/a 1/1000 CC1 32/Ab 12 
AE1/AE3 MAB3412 Chemicon Mouse n/a n/a 1/500 CC1 32/Ab 24  
EGFR 31G7 Life 
Technologies 
Mouse 1/1000 n/a 1/100 P2 16/Ab 60 
HER3 DAK-H3-
IC 
DAKO Rabbit 1/1000 n/a 1/100 n/a 
HER2 4B5 Roche Rabbit n/a n/a Pre-dilute CC1 32/Ab12 
p16Ink4a E6H4 Roche  Mouse n/a n/a Pre-dilute 
1/2 
CC1 32/Ab 8 
MIB-1 M7240 DAKO  Mouse n/a n/a Pre-dilute CC1 32/Ab 32 
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p53  CM5p Leica 
Biosystems 
Mouse n/a n/a 1/200 Citrate 
Antibodies are monoclonal unless otherwise specified. Optimised antigen retrieval time/primary antibody 
incubation time are indicated in minutes. Antigen retrieval solutions on the automated platform were CC1 (cell 
conditioner 1), CC2 (cell conditioner 2) and P2 (protease 2). Citrate buffer (pH 6.0) was used for heat retrieval of 
p53 antigen on the bench. All antigen retrieval was performed at 98°C. Ab, primary antibody incubation time. 
*Serial dilutions were performed with variable antigen retrieval and antibody incubation for these un-optimised 
antibodies (see Table 14 in Results).  
 
6.2 Tissue acquisition 
Tumour samples were collected from patients with large nerve perineural spread of cSCCHN 
treated surgically at the Princess Alexandra Hospital (PAH), Brisbane. Biopsy of the involved 
nerve was performed by the treating surgeon. Institutional ethics approval is in place 
(HREC/03/QPAH/197). Specimens were de-identified at the point of collection. A unique 
identifying code was assigned to each specimen and maintained in a secure database to allow 
subsequent review of the formal histopathological report and extraction of relevant clinical 
data. Specimens were FFPE and uniformly sectioned to 5µm. In all cases a routine 
haematoxylin and eosin (H&E) stain was performed on 1-2 sections of the research block to 
histologically confirm the presence of SCC with perineural spread within the block. Not all 
subsequent serial sections contained nerve tissue but sufficient SCC was present for analysis 
and considered representative of tumour that had undergone perineural spread. Specimens 
without evidence of perineural spread in the research block or sufficient tumour present in 
serial sections were excluded from this study.  
 
Twenty-one tissue biopsies were collected from the PAH over an 18-month period. A further 
18 blocks of confirmed PNS from cSCCHN (collected 2003-2011 at the Princess Alexandra 
Hospital under the same institutional ethics approval) were generously provided by our 
collaborators at QIMR. These blocks had previously been retrieved from QLD pathology 
archives and subject to independent histopathological review. Routine H&E stains were 
performed to ensure sufficient tumour remained in each block for analysis. 
 
6.3 Immunohistochemistry 
IHC was performed on the Ventana Discovery Ultra auto-staining platform (Ventana Medical 
Systems, Inc. USA). Protocol optimisation was performed using appropriate positive control 
human tissue for each antibody. Antigen retrieval was enzymatic for EGFR and heat retrieval 
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with CC1 retrieval solution (pH 8.0) for other antigens. Primary antibody concentrations for 
IHC are reported in Table 6 and incubation was 1 hour at 36°C unless otherwise specified. The 
Ventana anti-HQ HRP detection system was used with pre-dilute IgG anti-mouse or anti-rabbit 
HRP-conjugated secondary antibodies incubated for 1 hour at room temperature (RT) unless 
otherwise specified. Colour development with DAB reagent and haematoxylin counter-stain 
were also automated on the staining platform. Slides were mounted and cover-slips applied by 
the TRI Histology Core Facility staff. Negative controls included omission of the primary 
antibody (secondary only control) and tissue negative for the protein of interest. A positive 
FFPE tissue control was included in each run to ensure reproducibility of staining.  
 
6.3.1 EGFR immunohistochemistry 
For the EGFR, in brief, specimens were dewaxed and pre-treated with Protease 2 enzyme 
retrieval solution for 16 minutes at 36°C. Primary antibody was manually applied to the slide 
at a volume of 100uL and at recommended concentration of 1/100 diluted in Ventana antibody 
diluent solution (Ventana Medical Systems, Inc. USA). Incubation was at 36°C for 1 hour as 
per manufacturer recommendation and an anti-mouse HQ HRP detection system was used. 
DAB and haematoxylin counterstain were applied. Positive control was EGFR positive 
mucosal HNSCC.     
 
Interpretation of EGFR immunohistochemistry was performed by two independent medical 
pathologists using two standardised scoring systems. Firstly, a clinically validated staining 
index, as described in Hirsch et al (2003), was calculated for each specimen by multiplying the 
percent (%) of stained tumour cells by average staining intensity graded from 0 to 4, giving an 
index between 0 and 400.(171) For the purposes of this score, positive tumour cell staining was 
defined as any IHC staining of tumour cell membranes above background level, whether 
complete or incomplete circumferential staining. By this scoring system, EGFR positivity is 
defined as a staining index score ≥200. The second scoring system used was the widely 
accepted histopathological four-point intensity score, where specimens are graded as negative 
(0), weakly positive (1+), moderately positive (2+) or strongly positive (3+) (Table 7). To 
receive a positive score, ≥10% tumour cells must exhibit strong membranous staining. By this 
method, moderately and strongly positive specimens are considered EGFR over-expressing. In 
subsequent analysis, only tumours that were positive by both scoring methods were considered 
positive for EGFR over-expression.  
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Table 7 Histopathologic scoring system for membrane receptor expression  
 
 
6.3.2 HER2 immunohistochemistry 
For HER2, pre-dilute clinical antibody was purchased and staining performed per manufacturer 
recommendations for the Ventana Discovery Ultra platform (Ventana Medical Systems, Inc. 
USA). In brief, specimens were dewaxed and pre-treated with CC1 retrieval solution (pH 8.0) 
for 32 minutes at 95°C. Primary antibody was incubated at 36°C for 12 minutes and an anti-
rabbit HQ HRP detection system was used. DAB and haematoxylin counterstain were applied. 
Positive control was a 4-in-1 HER2 cell line control slide supplied by the manufacturer, 
depicting four cell lines with the range of staining intensity, and an independent HER2 positive 
breast cancer tissue control gifted by the PAH pathology laboratory. Specimens were scored in 
parallel to the 4-in-1 control slide with the standard four-point intensity score applied to 
membrane receptors, where specimens where graded 0 to 3+. To receive a positive score, ≥10% 
tumour cells must exhibit strong membranous staining (Table 7). 
  
6.3.3 p53 immunohistochemistry 
p53 immunohistochemistry was performed by the QIMR Berghofer Histology Facility using 
previously published methodology.(142) Appropriate positive and negative controls were 
included in each run. In our study, we performed immunohistochemistry for 10/20 specimens. 
The remaining 10 specimens had previously been immunostained at the same facility and the 
results published.(142) The raw data was generously provided by the authors for inclusion in this 
thesis and subsequent analyses and are attributed as such.  
 
In brief, tissue sections were de-waxed, rehydrated and incubated in 2% hydrogen peroxide for 
10 minutes. Antigen retrieval was performed in 10 mM citrate buffer for 8 minutes at 121°C. 
Sections were cooled, washed in TBS and blocked with Background Sniper (Biocare Medical, 
Concord, USA) for 15 minutes at RT. The p53 primary antibody (clone CM5p, Novacastra, 
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Nussloch, Germany) was then applied overnight at RT, and MACH1 Universal Polymer 
(Biocare Medical) applied for 45 min for detection. Sections were counterstained in 
haematoxylin, washed in water, dehydrated, cleared with xylene and mounted.  
 
Immunohistochemistry was assessed according to the method described by our collaborators 
at QIMR Berghofer based on earlier analyses published by Nyiraneza et al (2011).(142,147) Only 
nuclear staining was scored and tumours were deemed positive if any positive nuclear staining 
was observed or negative if none was observed. There was no cut-off value. The pattern of 
positive staining was qualitatively assessed as “diffuse positive over-expression” or “focal 
positive expression.” This allowed pooling of data with previous results from our collaborators, 
ensuring data for our entire cohort was available for subsequent analysis.  
 
6.3.4 p16 immunohistochemistry 
p16 immunohistochemistry was kindly performed by staff at the clinical pathology laboratory 
at the Princess Alexandra Hospital on a Ventana Benchmark Ultra platform. The clinically 
validated pre-dilute CINtec p16 antibody (E6H4, Roche) was used as per manufacturer 
recommendations. In brief, heat induced epitope retrieval was performed with CC1 retrieval 
solution (pH 8.0) for 32 minutes. Primary antibody was incubated for 8 minutes at 36°C. A 
Ventana Optiview detection kit was used and haematoxylin counterstain performed. Positive 
control was p16 positive tonsil SCC.  
 
The method of scoring used by McDowell et al (2016) in their study of p16 status in nodal 
metastatic cSCCHN was applied in our study.(158) Both the intensity and proportion of positive 
tumour cell staining was assessed. The stain intensity was scored on a 4-point scale: 0 (no 
staining), 1 (weak), 2 (moderate) or 3 (strong). The proportion of tumour cells staining positive 
was scored as a percentage (0-100%). There is no universally accepted definition for p16 
positivity in cSCCHN and this has not previously been assessed in perineural spread. We 
utilised the cut-off employed by Beadle et al (2013) and McDowell et al (2016) in the context 
of recent studies of nodal metastatic cSCCHN.(159,172) This is the same cut-off used in clinical 
pathology laboratories when assessing oropharyngeal HNSCC for p16 status (verbal 
communication, Ian Brown, 2016). p16 positivity is defined as an intensity score of 2-3 present 
in ≥70% of tumour cells. Negative staining was defined as no staining in any tumour cells. 
Specimens with any other degree of staining were classed as weakly positive. 
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6.3.5 Ki-67 proliferation index  
Ki-67 immunohistochemistry was performed by at Envoi Specialist Pathologists using an MIB-
1 antibody on their clinical autostaining platform. A control tissue slide with positive staining 
breast carcinoma cells and negative adipose tissue was included in each run. A single 
representative tumour-rich high powered field image was taken by an independent medical 
pathologist. The staining ratio appeared relatively uniform across individual specimens and the 
most tumour-rich hotspot was photographed for analysis. Interpretation of Ki-67 staining is 
difficult and prone to inter-observer variability. We combated this by utilising two scoring 
methods, a manual cell count and automated image analysis software. The proliferation index 
or proportion of Ki-67 positive cells, defined as strongly positive nuclear staining, was 
determined by counting all tumour cells within the field (≥ 50 tumour cells in all cases). Images 
with diffuse tumour were secondarily analysed using ImmunoRatio, a publicly available web 
application for quantitative image analysis, to externally validate the manual cell count 
results.(173) This plugin calculates the percentage of cells with a positively stained nuclear area 
using a colour deconvolution algorithm for distinguishing DAB and haematoxylin staining 
components. This automated method has been validated by several authors in breast and 
neuroendocrine tumours and compares favourably to manual methods.(164,173,174) There was a 
high degree correlation between the two methods in those specimens with diffuse tumour 
present, allowing the average of the two scores to be calculated.  In several specimens, a low 
number of tumour cells and an abundance of stromal and inflammatory elements, an inherent 
anatomical feature of perineural spread, limited application of the image analysis software, 
which significantly underestimated the proportion of positive staining. In these few cases the 
manual cell counts were used alone. The optimal Ki-67 cut-off for prognostic assessment is 
unknown, and values ranging between 15-30% have been suggested previously in breast 
carcinoma. Some authors have suggested using the median value of Ki-67 labelling index as a 
cut-off within a series.(164,173) In consultation with an independent medical pathologist, cut-offs 
of 15% and 30% were used to define three groups for qualitative reporting: low, intermediate 
and highly proliferative (verbal communication, Ian Brown, 2016). For the purposes of 
quantitative statistical analysis, we applied a cut-off value of 30% to differentiate low and 
highly proliferative groups.   
 
6.4 Cell Culture  
All cell lines were mycoplasma tested and verified mycoplasma free. Fixed human adult 
keratinocytes (HEKa) were obtained as a gift from Dr Glen Boyle (QIMR Berghofer, 
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Australia). A431, COLO16, SCC15 and HeLa tumour cell lines were obtained from the 
American Type Culture Collection (ATCC). A transformed KJD cell line (human keratinocytes 
infected with SV40 virus) was obtained as a gift from Professor Nicholas Saunders (UQDI, 
Australia). Tumour cell lines were maintained in Dulbecco’s Modified Eagle’s Medium: 
Nutrient Mixture F-12 (DMEM-F12) (Life Technologies, Gibco) supplemented with 10mM 
HEPES, 10% heat-inactivated foetal bovine serum (FBS) and 2mM of L-Glutamine (Life 
Technologies, Gibco). Cells were grown in a humidified incubator with 5% CO2 concentration 
at 37°C.  
 
6.5 SDS page and Western blot  
Cell lysates were prepared at 4°C with lysis buffer (1/1000 protease; 1/1000 phosphatase) and 
stored at minus 80°C. Cell lysates were sonicated and a Pierce BCA Protein Assay Kit (Thermo 
Scientific) was used per manufacturer recommendations to determine protein concentrations. 
Samples were diluted with H2O and x5 loading buffer to standardise protein concentration to 
1mg/ml. Equal volumes (18µL) of standardised samples were separated on 10% SDS-PAGE 
gel and transferred to methanol-activated PVDF membranes by electrophoresis. A pre-stained 
molecular weight marking ladder was run on each gel. Membranes were blocked in x1 TBST 
(20mM Tris-HCl, pH 7.4/137mM NaCl/0.1% Tween® 20) with 5% w/v nonfat dry milk for 40 
minutes with gentle shaking. Primary antibodies were diluted in 5% w/v BSA, x1 TBST at 
recommended concentrations and incubated overnight at 4°C with gentle mixing. Beta-tubulin 
was used as a loading control. Membranes were washed x 3 with TBST before 1 hour 
incubation at RT with horseradish peroxidase (HRP) conjugated secondary antibodies diluted 
to 1/10,000 in 5% w/v BSA, x1 TBST. Final washes were in TBST x 3 then TBS x 2 for 5 
minutes each. Proteins were visualized using enhanced chemiluminescence (ECL) reagents as 
per manufacturer guidelines and images acquired using Image-Lab Software (Life Science, 
New South Wales).      
 
6.6 Cell immunofluorescence  
Cells were plated on coverslips in 12-well plates to be approximately 80% confluent on the 
day of labelling. Cells were fixed with 4% paraformaldehyde (PFA) in PBS before 
permeabilization with 0.01% Triton TX-100 for 10 minutes at RT.  Cells were blocked with a 
solution of 1% bovine serum albumin (BSA) and 4% horse serum in PBS for 15 minutes at 
RT. Cells were labelled with primary antibody at RT for 1 hour at titrated concentration in 
blocking solution. An Alexa fluorophore-conjugated secondary antibody was then applied at a 
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concentration of 1/200 in blocking solution for 1 hour at RT (α-mouse-Alexa 555, α-rabbit-
Alexa 488 or α-goat-Alexa 594 were used depending on the primary antibody IgG). Coverslips 
were mounted in ProLong Gold (Invitrogen) on Superfrost slides. Confocal image acquisition 
was performed within 48 hours. The HeLa cell line was included as an expected negative 
control for each anti-Eph receptor antibody as this cell line is reported to express very little to 
no detectable levels of Eph receptor (The Human Protein Atlas, www.proteinatlas.org).(175) 
Secondary only negative controls were also included for each antibody. Antibody specificity 
was assessed by Western blot prior to immunofluorescence studies.        
 
6.7 Tissue immunofluorescence  
Human tumour specimens were FFPE then serial sectioned at 5µ onto positively charged 
Superfrost slides as previously described. Sections were dewaxed by heating in a 37°C oven 
for 30 minutes and soaking in xylene for 10 minutes. Rehydration in serial dilutions of EtOH 
at 100% for 5 minutes and 90%, 80%, 60% and 40% for 1 minute each was undertaken before 
soaking in H2O for 5 minutes. Heat-induced epitope retrieval (HIER) or enzymatic antigen 
retrieval was performed specific to the primary antibody. For HIER either 10mM sodium 
citrate buffer (pH 6.0) or 10mM/1mM Tris-EDTA buffer (pH 9.0) were used. Retrieval solution 
was brought to boiling in a microwave oven before slides were submerged for a total of 2 
minutes with temperature maintained between 90-98°C. Slides were washed in PBS x 2 for 5 
minutes each. Tissue sections were ringed with a wax pen and incubated in a blocking buffer 
(BB) of 1% BSA, 4% horse serum, 0.1% Triton X-100 in PBS for 1 hour at RT. Primary 
antibody was diluted in BB with Triton and incubated overnight at 4°C. The next morning 
slides were warmed to RT for 15 minutes before washes in BB for 5 mins x 3 then application 
of an IgG specific Alexa fluorophore-conjugated secondary antibody (1/200) for 1 hour at RT 
in the dark. Slides were protected from ambient light from this point onwards. Wash in BB x 
3 was performed prior to DAPI counter-stain at 1/10,000 for 10 minutes at RT. Sections were 
washed briefly with PBS and ddH2O before being coverslip mounted with ProLong Gold. 
Slides were stored in the dark at 4°C until image acquisition was performed.  
 
6.8 Microscopy 
Cell immunofluorescence experiments were analysed using a Zeiss 510 Meta laser scanning 
confocal microscope with x25 and/or x63 oil objective lenses. Emission wavelengths of 
405nm, 488nm and 555nm were used for blue, green and red fluorescence, respectively. 
Images were acquired using Zen 2009 software (Carl Zeiss Microscopy, Germany). Images 
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were analysed using Adobe Photoshop and Image J 1.48 for Mac OS X 10.7. Tissue 
immunofluorescence images were acquired on an Aperio FL Scanner (Leica Biosystems, IL, 
USA) at x20 magnification at the QIMR Berghofer Core Imaging Facility. Images were 
analysed in WebScope and minimally adjusted for brightness and contrast parameters to 
enhance visualisation of staining patterns. Appropriate positive and negative controls were 
imaged and analysed with identical parameters. In select cases high resolution images were 
acquired at x20 and x40 magnification with the Olympus FV1200 confocal microscope at the 
TRI Microscopy Core Facility using FV10i software (Olympus Microscopy, USA). Brightfield 
microscopy was used to visualise immunohistochemistry results. Slides were scanned with an 
Aperio slide scanner and digital slides viewed with OlyVIA software for scoring (Olympus 
Microscopy, USA).       
 
7.0 Results 
 
7.1 Cell line data 
7.1.1 Eph and ErbB receptor expression in SCC cell lines  
We aimed to assess expression of Eph and ErbB receptors in SCC cell lines. Western blots 
were performed for EphA2, EphA3, EphB1, EphB2, EGFR and HER3 receptors across four 
SCC cell lines and one human epidermal keratinocyte cell line. A431 is a human cutaneous 
carcinoma cell line derived from an epidermoid carcinoma in an 85 year old patient and is 
known to be highly EGFR over-expressing.(176) The COLO16 cell line was first derived from 
a metastatic cutaneous SCC in a 59 year old patient.(177) KJD is a keratinocyte cell line produced 
by transforming normal keratinocytes with the SV40 virus (KJD-1/SV40) and were prepared 
by and received as a gift from the Saunders laboratory (UQDI, Australia).(178) Together these 
three cell lines represent a spectrum of cutaneous SCC. The SCC-15 cell line (ATCC No. CRL-
1623) is derived from a tongue SCC in a 55-year-old patient, representing mucosal HNSCC. 
Primary human epidermal keratinocytes were received as a gift from the Boyle laboratory 
(QIMR Berghofer, Australia) as a normal epithelial control cell line. To our knowledge, there 
are no established cell lines derived from perineural spread cSCCHN.  
Representative Western blots for Eph and ErbB receptors in human epidermal keratinocytes 
and SCC cell lines are depicted (Figures 12, 14). All blots were performed in triplicate and 
histograms quantifying the results have been first normalised to β-tubulin as loading control 
and then normalised to HEKa expression, as the control cell line, to obtain a uniform y-axis. 
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Results were then averaged to depict mean signal intensity and standard deviation in arbitrary 
units (Figures 13, 15). Appropriate molecular weight bands were identified for EphA2 (125 
kDa), EphA3 (135 kDa), EphB1 (130 kDa), EphB2 (130 kDa), EphB4 (135 kDa), EGFR (175 
kDa) and HER3 (185 kDa) in each of the SCC cell lines and HEKa cell line indicating at least 
baseline level expression across these benign and malignant epithelial cell lines. Single high 
intensity bands at the appropriate molecular weight were seen for the EphA2 (125kDa) and 
EphB4 (135kDa) receptors using Cell Signalling Technology (CST) antibodies, confirming the 
specificity of the antibodies and the expression of the receptor in each of the cell lines 
examined. Similarly, an appropriate band was detected for the EphB2 (130kDa) receptor using 
an R&D Systems antibody. Although appropriately sized bands were detected for EphA3 
(135kDa) and EphB1 (103kDa) using Santa Cruz Biotechnology (SCBT) antibodies, there was 
significantly more background staining on the blots despite identical conditions. Furthermore, 
the presence of lower molecular weight bands on the blots in both instances suggests either 
non-specific binding of the primary antibody or alternatively the presence of splice variants or 
protein cleavage products for these proteins.  
The degree of Eph receptor expression qualitatively appears variable across the cell lines when 
examining the blots in combination with the loading control β-tubulin (Figure 12). Quantitative 
analysis confirmed that on average, expression of EphA2 receptor was higher in SCC cell lines 
compared to HEKa cells across the board, but particularly elevated in the A431 cell line with 
a >1.5 fold-change. Increased expression of the EphB2 was more significant with all SCC cell 
lines exhibiting high expression levels relative to normal keratinocytes with the A431 cell line 
again showing the most significantly elevated protein levels. Relatively high EphB4 expression 
was observed in COLO16 cells but was no different in other SCC cell lines when normalised 
to the loading control and HEKa cell line. EphA3 and EphB1 receptor expression was relatively 
stable across the malignant and control cell lines.    
Qualitative and quantitative expression of the EGFR was examined across the cell lines with a 
commercial antibody (clone 31G7, Life Technologies) (Figures 14, 15). EGFR expression in 
known highly over-expressing A431 cells was as expected significantly higher than all other 
cell lines, with a near 50-fold increase. Expression in COLO16 and SCC-15 cell lines was also 
increased relative to normal epidermal keratinocytes by 2-3-fold. The SV-40 virus 
immortalised KJD cell line had low EGFR expression comparable to the control HEKa cells. 
HER3 expression demonstrated a similar pattern across the cell lines although with less marked 
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fold-changes observed. A431, SCC-15 and COLO16 cell lines had an approximately 6-fold, 4-
fold and 2-fold change respectively compared to HEKa cells. Again, the transformed KJD cell 
line had a low expression of this RTK which was comparable to untransformed HEKa cells. 
 
 
 
Figure 12 Western blot analysis of EphA2 (125kDa), EphA3 (135kDa), EphB1 (130kDa), EphB2 
(130kDa) and EphB4 (135kDa) receptor expression in HEKa, COLO16, A431, KJD and SCC15 
cell lines. 18µg of whole cell protein lysates were separated on 10% SDS-PAGE and 
immunoblotted for the protein of interest. Experiments were performed in triplicate. Blots were 
re-probed for β-tubulin which served as a loading control reference protein. Representative 
images are shown. 
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Figure 13  Quantified Western blot analysis of Eph receptor expression in HEKa, COLO16, A431, 
KJD and SCC15 cell lines. Western blots were performed in triplicate. Western blot bands were 
quantified using ImageLab (Bio-Rad) and the signal normalised to β-tubulin as a loading control 
and then to HEKa expression as a normal epithelial cell line. Mean and standard deviation are 
depicted with signal intensity expressed in arbitrary units. 
 
Figure 14  Western blot analysis of EGFR (175kDa) and HER3 (185kDa) expression in HEKa, 
COLO16, A431, KJD and SCC15 cell lines. 18µg of whole cell protein lysates were separated 
on 10% SDS-PAGE and immunoblotted for EGFR (A) and HER3 (B), respectively. 
Experiments were performed in triplicate. Blots were re-probed for β-tubulin which served as a 
loading control reference protein. Representative images are shown. 
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Figure 15  Quantified Western blot analysis of EGFR (A) and HER3 (B) receptor expression in 
HEKa, COLO16, A431, KJD and SCC15 cell lines. Western blots were performed in triplicate. 
Western blot bands were quantified using ImageLab (Bio-Rad) and the signal normalised to β-
tubulin as a loading control and then to HEKa expression as a normal epithelial cell line. Mean 
and standard deviation are depicted with signal intensity expressed in arbitrary units.  
7.1.2 Eph receptor localisation in SCC cell lines   
Following assessment of antibody specificity by Western blot and initial quantified expression 
analyses, cell immunofluorescence was employed to localise Eph receptor expression at a 
subcellular level across the cell lines. Increasing evidence suggests that it is not simply receptor 
level of expression but cellular localisation of the receptor that is important in tumour biology 
and targeting treatment. EGFR and HER3 localisation studies have previously been performed 
by our laboratory and others so these experiments were not undertaken. However, given the 
minimal data on expression of Eph receptors in SCC cell lines, we labelled for each of EphA2, 
EphA3, EphB1, EphB2 and EphB4. We were unable to complete immunostaining for EphB1 
and EphB2 staining on KJD or SCC-15 cell lines due to a limited supply of the respective 
monoclonal antibodies. A secondary only negative control was included in each experiment 
and images acquired under identical conditions. The HeLa cell line (ATCC CCL-2) was used 
as a further negative control for EphA and EphB receptor antibodies as this cell line expresses 
very little to no detectable levels of these receptors.  
 
A summary table of cellular localisations of Eph receptors in human epidermal keratinocyte 
(HEKa) and tumour cell lines (COLO16, A431, KJD, SCC15) is included below (Table 8). 
Corresponding figures depicting representative images are included in Appendix A. All cell 
immunofluorescence was performed in duplicate in each of two separate experiments. Cellular 
localisation has been reported based on the predominant staining pattern observed: cytoplasmic 
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punctate endosomal staining (C) or membranous cell surface staining (M), and intensity 
qualitatively graded as 1+ to 3+ where positive staining was observed. In our study we have 
categorised predominant punctate cytoplasmic staining as endosomal staining. Work was 
completed with specimen sections available and remaining sections will be analysed by co-
localisation with endosomal markers to validate endosomal staining.     
 
Consistent with immunoblot results EphA2 had high levels of expression across all cell lines 
with strongly positive plasma membrane staining and minimal cytoplasmic expression 
observed. Relatively more intense staining was observed in tumour cells lines consistent with 
upregulation of the receptor at the cell surface. EphA3 had consistent levels of cytoplasmic 
expression across the cell lines with minimal plasma membrane staining detected. EphB1 
expression was similarly localised to endosomes within the cytoplasm with greater staining 
intensity observed in the COLO16 cell line compared to the HEKa and A431 cell lines. 
Notably, EphB2 predominantly localised to the cell membrane in COLO16 and A431 cell lines 
whereas in control HEKa cells it was largely cytoplasmic in expression, suggesting relocation 
or trapping of the receptor at the cell surface in the malignant cell lines. EphB4 expression was 
similarly intensely membranous in the COLO16 and KJD cell lines. Interestingly, minimal to 
no detectable EphB4 in the A431 cells or normal keratinocytes. These findings are consistent 
with the preceding Western blot analyses.         
 
Table 8 Predominant localisation of Eph receptors in human cell lines by immunofluorescence 
Cell lines Keratinocyte  Squamous cell carcinoma Control Corresponding 
figures 
(Appendix A) 
Localisation HEKa COLO16 A431 KJD SCC15 HeLa 
EphA2 M+ M++ M++ M+++ M+++ Neg A1 
EphA3 C++ C++ C+ C+++ C+ Neg A2 
EphB1 C+ C++ C+ n/p n/p Neg A3 
EphB2 C+ M+ M+ n/p n/p Neg A4 
EphB4 Neg M++ Neg M+ Neg C+ A5 
Key: M = predominantly plasma membrane staining; C = predominantly cytoplasmic staining; graded 1-3 (+, ++, 
+++); n/p = not performed; Neg = negative (minimal or no detected expression) 
 
 
7.2. Tissue data 
 
7.2.1 Clinicopathological factors  
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A total of 21 research biopsies were collected from surgical resections of patients with 
suspected perineural spread of cSCCHN over an 18-month period. All specimens were FFPE 
as previously described. The formal histopathological report and clinical data were reviewed 
for each patient. On formal histopathology 2 patients were found to have perineural spread of 
melanoma, 1 patient had adenoid cystic carcinoma and 1 had no tumour in the specimen and 
were thus excluded from the study. One patient had perineural invasion at the advancing 
tumour front but no large nerve perineural spread while 1 patient had indiscriminate invasion 
of structures including nerve tissue. Both were excluded from this study of clinical perineural 
spread. The 15 remaining patients had histologically confirmed perineural spread of cSCCHN 
documented in the formal pathology report. Review of 1-2 H&E stained transverse and/or 
longitudinal sections was performed for each research block to confirm the presence of 
sufficient tumour for experimentation. In 5 research blocks, insufficient tumour cells were 
identified on serial sections to facilitate immunostaining for proteins of interest. Thus, these 
blocks were excluded from the study. This left a total of 10 research specimens collected within 
our study timeframe with histologically confirmed cSCCHN with PNS within the research 
block for our study.  
 
To increase the size of our cohort, a further 18 research blocks were generously provided by 
our collaborators at QIMR Berghofer, having been previously collected under the same 
institutional ethics approval between 2003-2011. These blocks had previously been retrieved 
from QLD pathology archives and subjected to independent histopathological review to 
confirm perineural spread cSCCHN. Data has previously been published for this cohort by our 
collaborators.(142) Repeat H&E section and pathologist review was performed which revealed 
insufficient tumour remaining in the block for 6/18 specimens, leaving 12 additional research 
specimens for our study. Two specimens could not be re-identified meaning we were unable 
to independently review the formal pathology reports and clinical data could not be extracted. 
These patients were excluded from this study, leaving us a total of 20 specimens for this study. 
Clinicopathological factors and biomarker expression status, as determined by 
immunohistochemistry, are documented below (Table 9).  
 
Of the 20 specimens, one did not have differentiation specified in the formal report and we 
were unable to retrieve the block from archive to make an equivalent assessment. Of 19 
specimens, 8 (42%) were poorly differentiated; 10 (53%) were moderately differentiated and 
1 (5%) was well differentiated. With respect to the primary lesion, 55% (11/20) had an 
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identifiable primary while in 2 cases (10%) the primary could not be assessed and in 7 cases 
(35%) the primary was unknown (i.e. there was no history of a likely index lesion). The median 
time from symptom onset to diagnosis of perineural spread in our cohort was 4 months (range, 
1-60 months), with a mean of 10.7 months.    
 
Table 9 Histopathological data and biomarker expression profile by immunohistochemistry 
Perineural spread  Primary lesion  Biomarkers in PNS 
Block 
ID 
Diff. Identifiable Diff. Time to diagnosis Ki-67 
PI (%) 
p16 p53 
56 mod yes poor 8 35.8 pos neg* 
57 mod yes poor 1.5 20.4 neg diffuse* 
62 mod T0 n/a 2 22.7 weak focal* 
63 poor yes mod 3 23.1 pos focal* 
67 well yes well 2 22.7 weak diffuse* 
69 mod yes mod 42 19.5 neg neg* 
70 poor yes mod 5 32.9 weak diffuse* 
71 mod TX n/a 6 38.3 pos diffuse* 
72 mod yes poor 16 18.8 neg diffuse* 
73 poor T0 n/a 7 12.2 weak neg* 
T2 mod yes n/s 1 13.2 weak focal 
T6 poor TX n/a 2.5 35.1 neg diffuse 
T10 poor T0 n/a 12 15.4 weak focal 
T13 poor T0 n/a 2.5 32.1 pos diffuse 
T21 poor T0 n/a 2 55.4 weak focal 
T22 n/s T0 n/a 60 19.3 pos diffuse 
T26 poor yes well 24 31.8 neg diffuse 
T27 mod yes n/s 1 35.5 pos diffuse 
T28 mod T0 n/a 3 34.8 weak focal 
T31 mod yes mod 13 45.0 weak focal 
All reported cases (n=20) had clinical perineural spread of cSCCHN prior to resection and confirmed perineural 
spread cSCCHN on formal pathology. All research blocks had tumour in serial sections on assessment by two 
independent medical pathologists. Diff, differentiation grade; PNS, perineural spread; PI, proliferation index; time 
to diagnosis, time to diagnosis of perineural spread from symptom onset; well, well differentiated; mod, 
moderately differentiated; poor, poorly differentiated; T0, unknown primary; TX, primary not assessable; n/s, not 
specified; n/a, not applicable. *indicates p53 immunohistochemistry staining data published by Warren et al 
(2016) and used with permission.(142)  
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7.2.2 Expression of cell cycle molecular biomarkers in cSCCHN with PNS  
A proportion of tumour cells in all specimens had nuclear positivity for Ki-67 expression, with 
a range of calculated proliferation indices (Table 9). The mean Ki-67 proliferation index was 
28.2% and the median value 27.5% (range, 12.2% to 55.4%). Using a 3-tiered grading system 
a high proliferation index (>30%) was observed in half the cohort, a moderate proliferation 
index (15-30%) in 8 specimens and a low proliferation index (< 15%) in 2 specimens (Table 
10). As per previously published studies, with a mean and median value approximating 30% 
we used this as single-point cut-off to differentiate two groups (<30%, lowly proliferative; 
≥30%, highly proliferative) for the purposes of statistical analysis. Representative images of 
Ki-67 staining and ImmunoRatio analyzed pseudo-images are shown (Figure 16).    
 
 
Figure 16 Immunohistochemical detection of Ki-67 protein in cSCCHN with PNS. 
Representative image of Ki-67 nuclear staining (brown) is shown for a specimen of perineural spread 
of cSCCHN. The proliferation index (PI) is calculated by the number of positively stained tumour cells 
divided by the total number of tumour cells in the field. (A) Top panel shows the original representative 
high powered field image taken by an independent pathologist. Manual count of tumour cells yielded a 
PI of 22.7%. (B) Lower panel shows the pseudo-image constructed by the ImmunoRatio colour 
deconvolution algorithm to facilitate automated calculation of proliferation index.(173) ImmunoRatio 
calculated PI was 5% in this case. Given the abundance of stromal elements in this specimen, the manual 
cell count was used for subsequent analysis. Scale bar: 200µm.  
B 
A 
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Table 10 Ki-67 proliferation index calculated by immunohistochemistry  
Grade Ki-67 proliferation index cSCCHN with PNS (n=20) 
Low < 15% 2 (10%) 
Intermediate 15-30% 8 (40%) 
High > 30% 10 (50%) 
 
Of the combined cohort (n=20) of perineural specimens for which p53 data was available, half 
had diffuse positive over-expression, 7/20 (35%) had focal positive expression and 3/20 (15%) 
were negative for p53 expression by immunohistochemistry (Table 11). Representative images 
of the staining patterns in cSCCHN with PNS are shown (Figure 17). 
 
 
Figure 17 Immunohistochemical detection of p53 protein in cSCCHN with PNS. 
Representative images of p53 staining are shown at low (left panel, 40x) and high (right panel, 400x) 
magnification with nuclear p53 visualized in red. (A/B) negative pattern of p53 expression (no 
expression visualized in any tumour cell nuclei); (C/D) focal positive pattern of expression (strong 
expression within restricted areas of tumour in background of negative or weakly positive nuclei); (E/F) 
diffuse positive pattern of over-expression (very strong positivity throughout the tissue). Scanned 
images used with permission from the Boyle laboratory.(142) Scale bars: A, C, E are 500µm (40x); B, D, 
F are 50µm (400x).   
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Table 11 p53 expression pattern by immunohistochemistry 
p53 staining pattern cSCCHN with PNS (n=20) 
Negative 3 (15%) 
Focal/restricted expression 7 (35%) 
Diffuse over-expression 10 (50%) 
 
Positive staining for p16 was observed in 15/20 (75%) of specimens with 5 (25%) showing 
negative staining for p16. However, only 6/20 (30%) reached the threshold for positive p16 
status (2-3+ staining in ≥ 70% tumour cells) with the remaining 9/20 (45%) specimens 
displaying only weakly positive staining below the threshold (Table 12). Representative images 
of p16 staining are shown (Figure 18).   
 
 
Figure 18 Immunohistochemical detection of p16 protein in cSCCHN with PNS. 
Representative images of p16 staining are shown at low (left panel, 10x) and high (right panel, 4x) 
magnification with nuclear p16 visualized in red. (A/B) negative staining; (C/D) weakly positive 
staining; (E/F) strongly positive staining meeting threshold criteria (nuclear staining intensity grade 2-
3 in ≥ 70% of tumour cells). Scale bars: A, C, E are 200µm (10x); B, D, F are 100µm (4x).  
 
Table 12 p16 expression status by immunohistochemistry 
p16 status cSCCHN with PNS (n=20) 
Negative (no staining) 5 (25%) 
Weakly positive (below threshold) 9 (45%) 
Strongly positive (≥70% cells intensity 2-3) 6 (30%) 
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7.2.3 EGFR is over-expressed in perineural spread cSCCHN with variable localisation 
Given the high specificity of the anti-EGFR antibody and a plausible potential role for EGFR 
in perineural spread of cSCCHN, this candidate drug target was selected for further analysis at 
the tissue level using immunohistochemistry. A total of 20 specimens of histologically proven 
PNS of cSCCHN were available. EGFR immunohistochemistry was performed as previously 
described and scoring was conducted by two independent pathologists (Table 13). Where 
scores differed, a consensus score was reached. Two scoring systems were used in parallel to 
reduce potential bias. High quality specific and reproducible staining was achieved with 
intensity graded 0 to 3+ or 0 to 4, respectively. The percentage of positively stained tumour 
cells was also recorded to allow calculation of the staining index as previously described. 
Representative images of positive EGFR staining in perineural spread cSCCHN are shown 
(Figure 19). Sectioning resulted in a combination of longitudinal and transverse sections 
relative to the nerve fascicles (Figure 20). Both perineural and intraneural tumour cells were 
observed to stain strongly positive for the EGFR (Figure 20).    
 
Figure 19 Immunohistochemical detection of EGFR in perineural spread of cSCCHN. 
Representative images of EGFR immunohistochemistry showing weakly (1+), moderately (2+) or 
strongly (3+) positive staining of formalin fixed paraffin embedded 5µm tissue sections of perineural 
spread of cSCCHN. Primary antibody was mouse anti-EGFR (clone 31G7, Life Technologies) with a 
rabbit anti-mouse HQ HRP detection system and DAB reagent used on the Ventana Discovery Ultra 
automated staining platform. Representative images at 10x magnification of 1+ (A, B), 2+ (C, D) and 
3+ (E, F) positive staining are shown. Moderate or strongly positive staining represents over-expression 
of the EGFR using this standardized scoring method. Scale bars: 100μm.  
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Figure 20 EGFR immunohistochemistry on perineural spread cSCCHN in longitudinal and 
transverse sections. This figure depicts strongly positive (3+) perineural (arrow) tumour cell staining 
in longitudinal (A) and transverse (B) sections of perineural spread cSCCHN. In longitudinal section 
(A) positive staining of intraneural (arrowhead) tumour cells is also seen. Primary antibody was mouse 
anti-EGFR (clone 31G7, Life Technologies) with a rabbit anti-mouse HQ HRP detection system and 
DAB reagent used on the Ventana Discovery Ultra automated staining platform. Scale bars: 100μm.  
 
Of 20 specimens, 18 (90%) scored ≥ 200 for the staining index, consistent with EGFR over-
expression. These specimens all also scored positive with the standard 0-3+ histopathological 
score (Figure 21).  
 
Figure 21 Results of two methods of scoring EGFR immunohistochemistry in perineural 
spread of cSCCHN. There was good correlation between the scoring systems with 18/20 (90%) 
specimens scored positive for EGFR over-expression using (A) a clinically validated staining index (% 
positive cells × staining intensity (0-4)) and (B) a standard histopathological score (0-3+).  
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For the 18 specimens scored positive for EGFR over-expression by both scoring methods, we 
went on to characterise subcellular localisation of the receptor using secondary 
immunofluorescence. Immunohistochemistry was of sufficiently high quality to allow 
preliminary assessment of predominantly plasma membrane staining compared to cytoplasmic 
compartment staining in the specimens, which was scored independently by a medical 
pathologist and the principle investigator. Secondary immunofluorescence was then conducted 
on the bench for all positive cases to validate the preliminary findings and allow high resolution 
imaging. Fluorescently labelled slides were scanned in their entirety at 20x magnification and 
images analysed using ImageScope software by the principle investigator in consultation with 
the supervising cell biologist. Where higher resolution imaging was required, image acquisition 
was performed with a confocal microscope at 40x magnification. Two patterns were 
differentiated: circumferential plasma membrane staining, consistent with cell surface 
expression, and cytoplasmic punctate staining, consistent with endosomal expression. All 
specimens positive for EGFR over-expression exhibited strong plasma membrane staining 
(n=18/18, 100%). Half (n=9/18, 50%) had concomitant cytoplasmic staining while 9/18 (50%) 
had strong circumferential plasma membrane staining in a “cobblestone pattern” with little to 
no detectable cytoplasmic expression by secondary immunofluorescence (Figure 22). Raw data 
(Table 13) and representative images of secondary immunofluorescent staining for EGFR in 
PNS of cSCCHN are shown below (Figures 23, 24).    
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Figure 22 EGFR subcellular localisation assessed by secondary immunofluorescence. 
Plasma membrane staining was observed in all specimens (n=18). Detectable concomitant cytoplasmic 
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staining was only observed in 50% (9/18) of specimens with the other 50% appearing to have exclusive 
plasma membrane localisation of the EGFR. 
 
Figure 23 Secondary immunofluorescence staining for EGFR in FFPE tissue of perineural 
spread of cSCCHN. Primary antibody was anti-EGFR (31G7) and secondary antibody Alexa-555 (red) 
conjugated anti-mouse IgG. Nuclei were counter-stained with DAPI (blue). Image acquisition was with 
an Aperio FL Scanner (Leica Biosystems, IL, USA) at 20x magnification. Images were viewed using 
WebScope software. Left image is at 10x and right image is at 20x magnification (of white boxed area). 
Scale bars: 200µm (left) and 100µm (right). 
 
Table 13 EGFR staining index, score and localisation assessed by immunostaining in perineural spread 
cutaneous squamous cell carcinoma of the head and neck 
 
Staining index IHC 
Score 
 
EGFR 
Status 
Localisation 
ID Proportion (%)  Intensity  Index Membrane Cytoplasm 
56 90 3 270 2 + yes yes 
57 40 1 40 1 - n/a n/a 
62 90 4 360 3 + yes no 
63 60 1 60 1 - n/a n/a 
67 100 3 300 3 + yes no 
69 70 3 210 2 + yes yes 
70 100 3 300 3 + yes yes 
71 70 4 280 3 + yes no 
72 80 3 240 3 + yes yes 
73 80 3 240 3 + yes yes 
T2 90 3 270 3 + yes yes 
T6 100 3 300 2 + yes yes 
T10 90 3 270 2 + yes no 
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T13 100 4 400 3 + yes yes 
T21 100 4 400 3 + yes no 
T22 100 3 300 3 + yes no 
T26 90 4 360 3 + yes no 
T27 90 4 360 3 + yes no 
T28 100 4 400 3 + yes yes 
T31 80 4 320 3 + yes no 
n/a = not applicable (immunofluorescence was only performed for immunohistochemically positive specimens) 
 
 
Figure 24 Confocal imaging of secondary immunofluorescence for EGFR in FFPE tissue 
sections of perineural spread of cSCCHN. Primary antibody was anti-EGFR (31G7) secondary 
conjugated anti-mouse Alexa-555. Nuclei were counter-stained with DAPI (blue). Images are displayed 
from left to right as isolated blue channel (DAPI), isolated red channel, merged image at 20x and 
merged image at 40x magnification (area highlighted by white box). Images were analysed using 
ImageJ software. Top panel shows plasma membrane staining, middle panel shows punctate endosomal 
staining within the cytoplasm and lower panel is secondary only negative control on mucosal HNSCC 
tissue. Scale bars: 50µm.   
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7.2.4 Perineural spread of cSCCHN has low expression of HER2  
Immunohistochemistry for HER2 was similarly performed on the 20 tumour specimens 
meeting inclusion criteria. Known HER2 positive breast carcinoma and a 4-in-1 manufacturer 
supplied cell line control slide were used as positive controls and included in each run to ensure 
reproducibility of staining. A standardized IHC scoring method was used (Table 7). No 
specimens had detectable HER2 membrane expression by immunohistochemistry (Figures 25, 
26). Given the absence of detectable antigen immunofluorescent studies were not performed.      
 
Figure 25 Immunohistochemistry for HER2 protein in formalin fixed paraffin embedded 5-
micron tissue sections of perineural spread of cSCCHN. Representative images are shown at x10 
magnification. (A) HER2 positive breast carcinoma was used as a positive control. (B) None of 20 
perineural spread cSCCHN specimens were positive for HER2 staining in our cohort. The primary 
antibody was a clinically validated rabbit anti-HER2 (clone 4B5) monoclonal antibody with a goat anti-
rabbit HQ HRP detection system and DAB reagent on the Ventana Discovery Ultra automated staining 
platform. Scale bars: 100μm. 
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Figure 26 Results of scoring HER2 staining on perineural spread of cSCCHN. None of 20 
specimens had detectable HER2 antigen by immunohistochemistry in our cohort.  
 
7.2.5 Further optimisation of tissue immunostaining for HER3 and Eph receptor proteins 
is required in FFPE tissue 
Given the high specificity of antibodies to the EphA2, EphB2 and EphB4 receptors and their 
variable expression and localisation patterns across the previously examined SCC cell lines, 
we proceeded to optimisation experiments for immunostaining protocols with these antibodies. 
Given the notable positive and negative findings with EGFR (ErbB1) and HER2 (ErbB2), 
respectively, we also aimed to achieve tissue staining for HER3 across our cohort. Given 
questionable specificity of the EphA3 and EphB1 antibodies available to us and no significant 
variation in expression level or localisation observed in SCC cell lines compared to the HEKa 
cell line, no tissue work was pursued with these antibodies. 
 
The Human Protein Atlas database (www.proteinatlas.org) was used to review expression of 
each target receptor across a range of normal and malignant tissue.(175) Together with 
manufacturer recommendations, this information was used to select appropriate positive 
control tissues for optimisation experiments. Available selected tissues were generously gifted 
by the PAH pathology laboratory from their control stock and are tabulated below (Table 14).  
 
Secondary immunofluorescence was first performed at the bench using the previously 
described method. Antigen heat retrieval was performed using a microwave oven with retrieval 
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solution specific for the antibody as per the manufacturer datasheet (Table 14). Both acidic 
(citrate, pH 6.0) and basic (EDTA, pH 8.0) retrieval solutions were trialled for the EphB2 
receptor antibody. Serial dilutions of the primary antibody were based on the recommended 
starting concentration for immunohistochemistry (Table 14). Primary antibody incubation was 
overnight at 4°C while an appropriate Alexa fluorophore conjugated secondary antibody (anti-
rabbit or anti-goat) was diluted 1/200 and incubated in the dark for 1 hour at RT. Appropriate 
secondary only negative controls were included in each experiment. Image acquisition with 
confocal microscopy revealed no specific fluorescent labelling above background across the 
selected tissues for each of the four receptors. 
 
To ensure these negative results were not a consequence of failings in our laboratory HIER 
method or high background due to autofluorescence, we attempted immunohistochemistry for 
EphA2, EphB4 and HER3 on the automated Ventana Discovery Ultra platform. An anti-goat 
HQ HRP detection system was not available for the Ventana platform at our institute, thus no 
further experiments were attempted with the anti-EphB2 antibody. Target retrieval solution 
was again based on the antibody datasheet recommendations at incubated for standard on the 
automated platform, 32 and 64 minutes, respectively. Serial dilutions across three positive 
control tissues were performed (Table 14). Brightfield microscopy revealed no positive 
staining across these tissues for the three antibodies.  
 
Given the inability to achieve positive staining in FFPE control tissues with anti-Eph receptor 
antibodies, we sought advice from collaborators with experience in this field. Verbal 
communication with the Boyd laboratory at QIMR Berghofer, who work extensively with the 
ephrin/Eph receptor family, confirmed that staining in FFPE tissues with the current generation 
of anti-Eph receptor antibodies is inconsistent and unreliable. Certainly, the standard 
approaches to optimisation of both immunofluorescence and immunohistochemistry we 
employed on archival pathology tissue were unsuccessful. Given limited tissue availability and 
cost constraints a decision was made to pause further attempts at optimising anti-Eph receptor 
immunostaining and continue to focus experimental tissue work on the ErbB receptor family.  
 
As reported earlier, immunohistochemistry for both EGFR and HER2 with commercially 
available antibodies was successfully optimised on the Ventana automated platform, with 
highly specific and reproducible staining achieved. Conversely, there is a lack of standardised 
immunohistochemistry based methods for detection of HER3 in FFPE tissue. A recent study 
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compared four commercially available HER3 antibodies and concluded that the monoclonal 
DAKO (DAK-H3-IC clone) is the only reliable currently available antibody for translational 
research.(179) The authors observed reproducible circumferential plasma membrane staining in 
80% of HER2 positive breast cancers when immunohistochemistry was performed on a DAKO 
autostainer.(179) Using this antibody on the automated Ventana research platform at our 
institute, with comparable basic antigen retrieval (CC1 pH 8.0), we were unable to attain 
positive staining in our small sample (n=2) of HER2 positive breast carcinoma or other 
potential positive control tissues at recommended dilutions of 1/50 and 1/100 (Table 14). Given 
tissue and cost constraints we were not able to proceed with further optimisation experiments 
at this time. This is an area for future research and certainly worth pursuing with DAKO 
retrieval solution and autostaining apparatus with a wider selection of HER2 positive breast 
cancer specimens as positive controls.  
  
Table 14 Optimisation immunostaining experiments for monoclonal antibodies to proteins of interest  
Antibody Serial dilutions Antigen retrieval Positive control  
EphA2 1/50, 1/100, 1/200 EDTA (pH 8.0) 
CC1 (pH 8.0)* 
Breast Ca 
Colorectal Ca/colon 
Gastric Ca/stomach EphB4 1/100, 1/250, 1/500 Citrate (pH 6.1) 
CC2 (pH 6.0)** 
EphB2 1/20, 1/50, 1/100 EDTA (pH 8.0) 
Citrate (pH 6.0) 
Colorectal Ca/colon 
Gastric Ca/stomach 
Cutaneous SCC 
HER3 1/50, 1/100 EDTA (pH 8.0) 
CC1 (pH 8.0)* 
Melanoma 
Breast Ca (HER2+) 
Colorectal Ca/colon 
* CC1 (Ventana cell conditioner 1 target retrieval solution, pH 8.0); **CC2 (Ventana cell conditioner 2 target 
retrieval solution, pH 6.0). Ca, cancer; SCC, squamous cell carcinoma; EDTA, ethylenediaminetetraacetic acid. 
 
7.2.6 Multiplex immunofluorescent labelling is a viable research strategy for investigating 
perineural spread of carcinoma 
As part of this thesis, double immunofluorescent labelling was performed in perineural spread 
cSCCHN. Pathology standard pan-cytokeratin (AE1/AE3) and anti-S100 antibodies were used 
to demonstrate labelling of epithelial tumour cells and nerve sheath myelin, respectively. The 
previously described secondary immunofluorescence method was applied with the two primary 
antibodies incubated concurrently overnight and two different Alexa fluorophore conjugated 
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secondary antibodies, anti-mouse Alexa-555 and anti-rabbit Alexa-488, incubated for 1 hour 
at room temperature. To our knowledge, this is the first double immunofluorescent staining 
reported in perineural spread of carcinoma (Figure 27). Previously double 
immunohistochemistry techniques have been applied with a view to increasing the detection 
of microscopic perineural invasion. This technique demonstrates that multiplex fluorescent 
labelling can be achieved with suitable high-specificity antibodies in this disease process. Such 
a technique is aptly suited to future experimental work given the anatomy of perineural spread 
and the importance in examining all components of the nerve-tumour microenvironment in 
dissecting the underlying mechanisms of invasion and spread.  
 
 
 
Figure 27 Confocal imaging of double immunofluorescent staining of FFPE tissue sections of 
perineural spread cSCCHN. Primary antibodies were AE1/AE3 pan-cytokeratin (red) and anti-S100 
(green) for epithelial tumour cells and myelin sheath, respectively. Secondary anti-mouse Alexa-555 
(red) and anti-rabbit Alexa-488 (green) antibodies were used, respectively. Nuclei were counter-stained 
with DAPI (blue). Representative image of perineural spread cSCCHN in transverse section at x63 
magnification is displayed from left to right as isolated blue channel (DAPI), isolated red channel 
(AE1/AE3), isolated green channel (S100) and merged colour image. Scale bar: 20μm.  
 
7.2.7 Biomarker profile and correlations in perineural spread of cSCCHN  
 
It is integral to consider the complete molecular profile of a malignant process, not just 
individual receptors or drug targets in isolation. EGFR over-expression and receptor 
localisation are compared for p16 status, p53 staining pattern and Ki-67 proliferation index (PI) 
in tables below (Tables 15, 16). Contingency table analysis in GraphPad Prism software was 
performed using two-tailed Chi-square analysis (significance, p<0.05) to examine possible 
correlations between these categorical variables. Specifically, we examined whether EGFR 
over-expression (positive, n=18 or negative, n=2) or EGFR staining pattern (plasma membrane 
only, n=9 or other staining pattern, n=11) were related to any of the three biomarkers assessed 
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by immunohistochemistry. Due to low numbers, for analysis by expression pattern, EGFR 
negative specimens (n=2) were combined with the group with concomitant plasma membrane 
and cytoplasmic expression (n=7), which was then compared as a single group to the plasma 
membrane only expression group (n=9). Each biomarker was then categorized into two 
clinically significant groups: p16 status was categorized as either positive or negative (negative 
and weak positivity groups combined), p53 staining pattern was categorized as abnormal 
(negative or diffuse positive over-expression) or normal (focal positive expression) and Ki-67 
PI re-categorized as lowly (<30%) or highly (>30%) proliferative. 
There was no statistically significant correlation between EGFR status and p16 status (p=0.52), 
p53 staining pattern (p=0.64) or PI (p=0.14) (Table 15). Similarly, there was no statistically 
significant relationship between EGFR staining pattern and these variables (p16, p=0.77; p53, 
p=0.42; PI, p=0.65) (Table 16). These analyses are largely limited by the small sample size and 
a larger data set is be required for more meaningful correlations to be examined. Moreover, 
once sufficient follow-up data is available, Kaplan-Meier survival analyses could be performed 
with rigorous univariate and multivariate analyses for these biomarkers and other 
clinicopathological factors.   
Given the variability in p16 status and p53 staining pattern, we also examined the relationship 
between these two variables, given the suggestion of possible distinct underlying mechanisms. 
There was no statistically significant relationship observed (p=0.63). We also performed 
Pearson coefficient linear regression analysis to assess correlation between Ki-67 proliferation 
index, a molecular biomarker for aggressiveness, and time from symptom onset to diagnosis 
of perineural, a clinical marker for aggressiveness. Low numbers limit conclusions however 
there was a trend towards correlation without reaching statistical significance in our cohort 
(p=0.29).  
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Table 15 Comparison of EGFR over-expression status and biomarker profile 
Biomarker  EGFR 
positive 
EGFR negative p-value 
p16 status 
 
Positive 5 (27.8%) 1 (50%) 0.52 
Negative 13 (72.2%) 1 (50%) 
p53 pattern 
 
Abnormal (negative or 
diffusely positive) 
12 (66.7%) 1 (50%) 0.64 
Normal (focally positive) 6 (33.3%) 1 (50%) 
Ki-67 PI 
 
Low (< 30%) 10 (55.6%) 0 (0%) 0.14 
High (> 30%) 8 (44.4%) 2 (100%) 
Chi-square analysis with two-sided p-value (n = 20, significance p<0.05). EGFR positive (n = 18) and negative 
(n = 2) refers to over-expression assessed by immunohistochemistry. PI, proliferation index. 
 
Table 16 Comparison of EGFR localisation pattern and biomarker profile 
Biomarker  Plasma 
membrane only 
Other pattern or 
no over-
expression 
p-value 
p16 status 
 
Positive 3 (33.3%) 3 (27.3%) 0.77 
 Negative 6 (66.7%) 8 (72.7%) 
p53 pattern 
 
Abnormal (negative or 
diffusely positive) 
5 (55.6%) 8 (72.7%) 0.42 
 
Normal (focally positive) 4 (44.4%) 3 (27.3%) 
Ki-67 PI 
 
Low (< 30%) 4 (44.4%) 6 (54.6%) 0.65 
 High (> 30%) 5 (55.6%) 5 (45.5%) 
Chi-square analysis with two-sided p-value (n = 20, significance p<0.05). PI, proliferation index. EGFR 
localisation assessed as either plasma membrane only (n = 9) or other pattern (negative or concomitant 
cytoplasmic staining, n = 11).  
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8.0 Discussion 
 
8.1 Eph and ErbB receptor expression is variable across SCC cell lines 
We examined expression of Eph and ErbB receptors across 4 representative SCC cell lines 
relative to a normal keratinocyte cell line. Expression of most Eph receptors/ephrin ligands is 
low in normal adult tissues compared to embryonic development where Eph/ephrin signalling 
is critical to a number of processes.(77) As described earlier, the dysregulation of expression of 
these RTKs is complex and observed in a wide range of malignancies.  
 
In normal human epidermal keratinocytes, EphA1, EphA2 and EphA4 are increasingly 
expressed with differentiation while EphA3 and EphB2 are expressed at very low levels.(180) 
Ligand activation of EphA2 has been shown to promote differentiation and adhesion via 
desmoglein 1.(181) EphB2 also promotes differentiation but through reverse signalling in normal 
skin.(182) Limited research has been conducted in cSCC tissue or cell lines. In chemically 
induced cutaneous mouse carcinoma, knockout of EphA2 was associated with tumour 
progression, suggesting a potential tumour suppressor role in normal keratinocytes. Similarly, 
downregulation of EphA1 has previously been observed in NMSC.(77)  
 
In our study, one HEKa cell line, three cSCC cell lines and one oral cavity SCC cell line were 
examined qualitatively and quantitatively for Eph receptor expression by Western blot and cell 
immunofluorescence. Western blot analysis confirmed at least low level expression for EphA2, 
EphA3, EphB1, EphB2 and EphB4 across the 5 cell lines. However, level and localisation of 
Eph receptor expression was variable and appeared to possibly be co-related to ErbB receptor 
expression. The significant membranous EphB2 expression in COLO16 and A431 cell lines 
we observed by immunofluorescence and immunoblotting supports recently published data 
that suggests a role for EphB2 in potentiating UVR induced cSCC. In the recent study by 
Farshchian et al (2015), tumour microarray (TMA) analysis revealed upregulation of EphB2 
and EphA4 in primary and metastatic cSCC cell lines compared with HEKa cell lines.(94) Eight 
SCC cell lines were established from surgically removed primary or metastatic cSCC and 
upregulation of EphB2 was verified by next generation sequencing and reverse transcriptase 
PCR. Evaluation of human cSCC tumours on TMAs revealed positive tumour-cell specific 
EphB2 staining on the cell surface and/or in the cytoplasm of both invasive cSCC and CIS. 
Subsequent knock-down experiments were performed demonstrating that EphB2 regulates 
proliferation, migration and invasion of cSCC cell lines in vitro and in a xenograft model.(94) 
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The cytoplasmic expression we observed in normal HEKs suggests relocation or trapping of 
the EphB2 receptor at the cell surface as a malignant phenotype. However, the very high EphB2 
receptor level in A431 cells on quantitative Western blots compared to the qualitative plasma 
membrane over-expression observed by immunofluorescence suggests at least a level of 
endosomal expression in the A431 cell line. Conversely, the KJD cSCC cell line did not appear 
to express EphB2 at significant levels at the plasma membrane by immunofluorescence. This 
cell line is transformed by a virus (SV40) and not derived from solar UVR exposed human 
skin, thus a dissimilar receptor profile is not unexpected. Similarly, this may account for the 
low receptor tyrosine kinase expression observed in the KJD cell line across the board, 
including the other Eph receptors, EGFR and HER3. Our data supports the notion that virus 
induced cancers may not be dependent or as dependent on receptor tyrosine kinase signalling.  
 
The role of EphA2 as a tumour suppressor gene in skin cancer suggested by previous studies 
in mice is somewhat challenged by our data.  The globally high levels of EphA2 expression 
across the SCC cell lines in our study would suggest overexpression as a key mechanism in 
concordance with recent clinical data associating EphA2 with tumour progression and poor 
survival.(84,183,184) A recent systematic review found EphA2 overexpression to be significantly 
correlated with poor overall survival in patients with various human carcinomas.(185) In our 
study, all four tumour cell lines had significant plasma membrane expression of EphA2 on 
immunofluorescence. Immunoblotting results were largely consistent with these findings. A 
relative discrepancy between the strong membranous staining observed in the SCC15 and A431 
cell lines and the much higher quantitative EphA2 expression by Western blot in the A431 cells 
can be explained by likely changes in epitope accessibility between denatured samples for 
Western blot compared to native structure in immunofluorescence studies. Moreover, Western 
blot assesses the entire protein complement whereas immunofluorescence is used to visualise 
subcellular patterns of protein expression, particularly plasma membrane staining. While our 
initial attempts at optimisation of immunohistochemistry and immunofluorescence for the 
EphA2 receptor in tissue were unsuccessful, ongoing improvements in the utility of 
monoclonal antibodies available for research applications may allow us to re-examine EphA2 
and other Eph receptors in perineural spread tissue in future work. Our laboratory also has a 
banked collection of specimens of actinic keratosis (AK), CIS and invasive cSCC and 
anticipate further study of EphA2 expression in this spectrum of primary carcinoma.  
The observation of high EphB4 expression in COLO16 cells relative to the A431 cell line, 
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could possibly reflect lower plasma membrane expression of EGFR and HER3 in the COLO16 
cell line. In the absence of dominant RTK signalling from ErbB family members, other surface 
receptors may be upregulated and potentiate kinase signalling. Our data revealed no significant 
patterns for the EphA3 or EphB1 receptors by immunoblotting or immunofluorescence. 
However, review of the Western blots suggests that these two antibodies were much less 
specific with significant background staining and multiple bands present. Based on our data a 
role for EphA3 and/or EphB1 in cutaneous carcinoma and its forms of metastasis can certainly 
not be excluded. Expression profiling of a large cohort of cSCCHN with perineural spread 
found a > 6-fold upregulation of the EphA3 receptor, thus further investigation is warranted.   
The cross-talk between membrane receptors in malignancy is an emerging area of research. 
Tumour heterogeneity is recognised as a key factor in tumour initiation, progression and 
resistance to therapy. For example, ligand-independent activity of EphA2 has been implicated 
in multiple cross-talks with EGFR and vascular endothelial growth factor (VEGF) pathways to 
promote migration, invasion and metastasis.(186) A recent study explored the cross-talk between 
the EphA2 and EGFR pathways in colorectal cancer.(187) Dual EphA2 and EGFR over-
expression had prognostic significance in patients with increasing disease stage and was 
associated with cetuximab resistance in stage IV patients, independent of KRAS mutation 
status. These results suggest EphA2 as a complementary biomarker to EGFR and as a possible 
mechanism of resistance to existing monoclonal antibody therapy. An earlier study in HNSCC 
suggested STAT-related profiles, including EphA2 status, predicted patient response to 
targeted treatments in locally advanced disease.(188) EphA2 and EphB2 gene expression were 
assessed on HNSCC tumour tissues with high EphA2 expressing tumours having higher 
response to combination cetuximab/radiotherapy and longer progression-free survival. Clearly, 
more work is required to define the exact mechanisms involved at different tumour sites, but 
given the observed expression in cSCC and HNSCC cell lines, the EphA2 pathway and its 
interactions with ErbB receptor signalling remains a candidate axis for future research at the 
cellular and tissue level in perineural spread cSCCHN.  
 
Although it is difficult to draw significant conclusions from largely qualitative cell line data, 
the representative cell lines we studied would appear to demonstrate that solar UVR induced, 
as opposed to virus transformed, SCC cell lines are more dependent on kinase signalling 
whether via ErbB receptors or Eph receptors. It is likely the balance of receptor expression and 
activity within each RTK family, and even the balance of the total complement of receptor 
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tyrosine kinases, that determines the malignant cell phenotype and potential for invasion, 
metastasis and/or perineural spread. Moreover, further understanding of the variable 
localisation of these receptors at steady and dynamic states will contribute to understanding the 
downstream pathways, targeting treatment and overcoming resistance. There is no doubt that 
RTKs have a significant role to play in cSCC and probably in perineural spread of the same. 
Eph expression and regulation is probably interdependent on other underlying tumour drivers, 
whether ErbB tyrosine kinase signalling or disruption of the p53 pathway.  
 
Future studies with a perineural carcinoma cell line would be advantageous but there are 
obvious anatomical and technical challenges involved in establishing such a cell line. 
Alternatively, knock-down studies using the in vitro DRG tumour co-culture model may be 
informative regarding the role Eph and ErbB receptor signalling and cross-talk plays in the 
nerve-tumour microenvironment.     
 
8.2 cSCCHN with perineural spread over-expresses EGFR which represents a potential 
therapeutic target  
We comprehensively examined EGFR expression and localisation in this relatively large series 
of perineural spread cSCCHN. Acquisition of sufficient tumour samples for meaningful 
analysis remains challenging given this is a relatively rare condition. At our tertiary institution 
in Queensland, Australia, we arguably see the highest number of cases per year of perineural 
spread cSCCHN of any centre worldwide due to the extraordinarily high incidence of NMSC. 
Of these approximately 25 cases per year are amenable to surgical resection. The inherent 
anatomy of perineural spread of carcinoma adds another level of difficulty. Research biopsies 
were not uncommonly found to lack sufficient tumour cells in serial sectioning for rigorous 
immunostaining experiments, unlike in diffuse solid tumour types. However, excellent 
recruitment over several years meant that 10 new samples in addition to 10 archived samples 
were available for our study, a relatively large and representative cohort for this disease. 
 
On review of the literature, EGFR overexpression is reported in up to 35% of primary cSCC 
and up to 58% of advanced, recurrent or nodal metastatic disease.(189,190) EGFR overexpression 
is documented in approximately one third of epithelial malignancies across colorectal, breast, 
ovarian, prostate, bladder and lung cancers.(191) In mucosal HNSCC it is well recognised that 
EGFR is highly expressed in 80-100% of tumours.(191,192) To our knowledge, this is the first 
study to look at EGFR expression in perineural spread of cSCCHN.  
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In our cohort, EGFR over-expression was observed in 90% (18/20) of specimens. The rate of 
over-expression appears significantly higher than that reported in primary cSCC lesions. 
Canueta et al (2016) recently evaluated a series of 94 cSCC with only 33 (35%) reported as 
having high EGFR expression on immunohistochemistry, although at least low level EGFR 
was detectable in 85 (90.4%) cases.(193) EGFR over-expression was associated with Ki-67 
proliferation index, TNM stage and nodal progression in this study. An earlier study by Ch’ng 
et al (2008) found a similar rate with 9/25 (36%) primary cSCC not associated with metastasis 
displaying EGFR overexpression.(190) The authors went on to look at nodal metastatic disease 
derived from 15 of these tumours and observed EGFR overexpression in 7/15 (47%). The 
highest rate of expression was seen in a sub-group analysis of just the primary lesions 
associated with metastasis (n=11/14, 79%). Although EGFR over-expression was prognostic 
for metastasis on multivariate analysis (p=0.05), over-expression was not conserved in 
metastatic lesions in 53% of cases. FISH analysis revealed EGFR over-expression was 
independent of gene amplification or mutation however localisation studies were not 
performed. Possibly, trapping of EGFR on the plasma membrane is an inciting or driving event 
in invasion and lymphatic dissemination, although the receptor may not play a critical role in 
established metastatic disease.  
 
Outside this study, there is a consistent general trend towards increasing level of EGFR 
expression in more aggressive or metastatic lesions reported in the literature. Maubec et al 
(2005) looked at EGFR and HER2 expression in a series of 13 metastatic recurrent SCC of the 
skin with 2 primary lesions also studied.(189) Weak HER2 expression was detected in 4/13 
(31%) specimens with only 2/13 (15%) displaying membrane positivity, and only in a small 
proportion of well-differentiated tumour cells. Using the now widely-standardized staining 
criteria for HER2 applied in our study, none of these specimens would have reached the 
threshold for positivity. On the other hand, strong plasma membrane staining for EGFR was 
reported by the authors in 13/13 (100%) metastatic lesions. They noted that 80% cells stained 
positive at 3+ intensity in every specimen, with a general comment that staining was strongly 
membranous and a single representative image shown. There is no comment on whether the 
IHC scoring was performed by an experienced medical pathologist and whether they were 
blinded to the study hypothesis. The authors used similar methodology with an identical anti-
EGFR mouse monoclonal antibody (31G7) at 1/100 and scored the percentage of positively-
stained cells per high-power field and intensity of staining as values 1+ to 3+. However, the 
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identical scoring attributed to all 13 metastatic lesions and 2 associated primary lesions (+++, 
80%) raises a concern. One other study examined both primary and metastatic cSCC lesions in 
5 patients and reported overexpression in 4/5 (80%) metastatic cases with corresponding but 
much lower intensity staining in the primary tumours.(194) A different mouse monoclonal 
antibody (H11) was used in this study. Krahn et al (2001) looked at co-expression patterns of 
EGFR, HER2, HER3 and HER4 in a small series of 5 cSCC lesions by mRNA analysis.(195) In 
cSCCs, 40% exhibited triple expression of EGFR/HER2/HER3 compared to 26% of normal 
skin samples.  
 
In unpublished data from our own laboratory, only 48% of cutaneous SCC (n = 58/120) were 
EGFR over-expressing on immunofluorescence studies (verbal communication, Fiona 
Simpson, 2016). Perineural spread is considered to be advanced disease and of note from the 
literature it is apparent that as disease stage increases, positivity for EGFR also increases. The 
finding that 90% of perineural spread cSCCHN over-expresses EGFR suggests that the EGFR 
in some way confers the potential for perineural invasion and spread. Certainly it remains 
unclear whether our finding simply is representative of the aggressive subset of tumours that 
undergo perineural spread or is indicative of a specific underlying mechanism. However, the 
finding that half of over-expressing specimens (9/18) appear to have relocation or trapping of 
the receptor on the cell surface, suggests dysregulation of receptor trafficking may be a 
significant mechanism. This finding also indicates that perineural spread is not a molecularly 
homogenous condition. There is significant tumour heterogeneity within the perineural spread 
cSCCHN cohort which has definite implications in targeting therapy.  
  
Subcellular localisation of the EGFR receptor is variable between specimens as demonstrated 
by our combined immunohistochemical and immunofluorescence approach, with 50% of 
EGFR over-expressing specimens in our series (9/18) having concomitant cytoplasmic staining 
consistent with internalised EGFR on endosomes. Previous live uptake experiments by our 
laboratory in HNSCC has demonstrated various subtype patterns where, in response to EGF 
ligand stimulation, EGFR may be polarised on the membrane or internalised on endosomes.(135) 
Earlier work in our laboratory, with the closely related HER2 receptor, has demonstrated the 
significance of tumour heterogeneity in terms of subcellular localisation of receptors targeted 
therapeutically. The EGFR normally internalises by ligand-induced endocytosis and thus in 
post-fixation steady state staining, such as shown by IHC, we would expect all positive tumour 
cells to show a degree of cytoplasmic staining. Thus, it is unusual that 50% of specimens show 
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only marked cell surface labelling with the characteristic cobblestone pattern. The escape of 
RTKs from internalisation and degradation has been suggested to be a new hallmark of 
cancer.(196) Tumour heterogeneity and dysregulation of receptor trafficking are now considered 
the most likely culprits for high rates of treatment failure and resistance development. For 
example, monotherapy with anti-EGFR antibodies has produced only modest response rates of 
5-15% in mucosal HNSCC in clinical trials.(197) Numerous different mutations lead to this 
phenotype of RTK escape and it will be of great interest to further examine whether such a 
high rate of RTK escape is a driving factor and amenable therapeutic target in perineural spread 
cSCCHN. This phenotype alone may represent a major mechanism of cSCC invading and 
tracking along the perineural compartment.       
 
However, dysregulation of EGFR trafficking is unlikely to be the only driving mechanism 
implicated in the process. As is described in cSCC, dysregulation of other pathways, including 
the p53 pathway, may make a significant contribution. Further studies are needed to better 
elucidate the molecular biology and correlate clinicopathological factors with EGFR status and 
expression pattern. Irrespective, EGFR expression may constitute a useful biomarker that could 
be used to predict disease behavior and allow patient stratification.  
 
Although there are certainly limitations in immunohistochemical detection and scoring of 
protein markers, by performing secondary immunofluorescence with highly specific 
monoclonal antibodies, we have internally validated our findings. We also aimed to limit bias 
by utilising two different scoring methods performed by two independent medical pathologists 
blinded to the study hypotheses. The advent of new techniques, such as in fluorescence situ 
hybridisation and gene mutation analysis, raises the potential for new complementary 
approaches to analysing potential drug target expression in future experiments. 
 
We did not perform testing on the index primary lesions in this series and acknowledge that 
this may have been informative. However, as reported in previous studies, up to 20% of PNS 
have no history of a primary lesion while in another approximately 20% cases it is impossible 
to identify the likely primary in the context of a history of multiple cutaneous malignancies in 
patients with widespread UVR induced field change. The most recent analysis of our 
institutional database show that 42% patients have an unidentifiable primary.(142) As expected, 
this was a consistent finding in our cohort where 45% had an unidentifiable or un-assessable 
index lesion. In future work, it would be useful to access tissue for those identifiable likely 
102 
 
primary lesions to assess whether EGFR status and other biomarkers correlate between the 
primary and subsequent perineural disease. However, we expect this may have limited clinical 
application given the large numbers with an unidentifiable primary. Resources may be better 
dedicated to other promising avenues of research.    
  
The logical next step to build on our finding of EGFR overexpression is application to the in 
vitro and in vivo models of perineural spread discussed earlier. Recent findings by our 
collaborators at QIMR demonstrate that the A431 cell line has a strong propensity for 
perineural invasion.(51) This research group utilized a popular in vitro DRG co-culture model 
and has also developed and optimized an in vivo murine model whereby tumour cells are 
injected subcutaneously into the cheek of Balb/c nude mice (Figure 7).(51) The whisker region 
is richly innervated by the maxillary division of the trigeminal nerve and models the proximity 
of the human division to high-risk mid-face cSCC. This is thought to be a higher fidelity model 
as it avoids direct injection of tumour cells into the nerve sheath, replicating the disease natural 
history in humans. In their in vitro study the highest rates of neurite outgrowth and tumour cell 
invasion were observed for the parenteral A431 cell line. Knockdown studies for LOXL2 and 
TGM3 did not significantly alter neurotropism. After initial optimization of cell injection 
counts, 6 of 7 (86%) mice injected with parenteral A431 cell line developed PNI. However, 
none developed perineural spread away from the main tumour bulk in the timeframe of mouse 
survival post tumour cell inoculation, in the setting of rapid primary tumour growth. On the 
other hand, no incidental PNI or PNS was observed histologically in any of the mice with 
tumours derived from the COLO16 cell line.(51) Further studies are underway to optimize the 
cell number injection required to allow sufficient time for perineural spread to occur before 
mandated euthanasia due to primary tumour bulk (verbal communication, Dr Glen Boyle, 
2016). Potentially, there may be a role for primary tumour excision to allow sufficient time for 
perineural invasion and spread to occur and thus replicate the natural history of perineural 
spread in humans.(51)  
 
The A431 cell line is known to express abnormally high levels of EGFR in culture and our 
work and that of many others supports this at a gene and protein level.(176) Given the increased 
levels of EGFR expression demonstrated in human specimens of perineural spread by our 
work, and our collaborators experience with this cell line in vivo, we suggest that it may be the 
EGFR receptor and/or RTK downstream signaling that facilitates perineural invasion in the 
first instance, as observed in the model, and then subsequent spread, as seen in our tissue work. 
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Regardless, EGFR overexpression appears to be a consistent feature implicated in the process. 
We anticipate further experimentation with the A431 cell line in the xenograft model including 
further knockdown studies. Alternatively, ethical approval could be sought for trial of an anti-
EGFR monoclonal antibody in mice with perineural spread. Radiological investigations may 
need to be validated to replace histopathological confirmation of perineural spread in this 
setting.   
 
EGFR is not currently considered a useful biomarker or prognostic factor in cutaneous SCC. 
Although it may be associated with an increased metastatic potential in some lesions, its 
expression does not appear to be conserved once metastasis has occurred.(190) Current response 
rates to EGFR monoclonal therapy in metastatic cutaneous SCC remain extremely poor.(198) 
However, our data suggests a potential role for EGFR in perineural spread and reveals a novel 
therapeutic target and possible biomarker in this subset of disease. In future, EGFR may be 
used to identify those primary lesions with an increased propensity to access and propagate 
along the perineural compartment. Knowledge of a patients EGFR status in combination with 
the presence of other adverse features such as the presence of microscopic PNI on original 
pathology and location on a high risk area (e.g. mid-face, forehead or lower lip) could inform 
follow-up protocols post primary resection. Such patients could be considered high risk for 
perineural spread and appropriate close clinical follow-up instituted, with a low threshold for 
MR neurogram to evaluate the trigeminal and/or facial nerves. Evaluation of index lesions, 
other clinicopathological factors and survival outcomes would be of benefit.   
 
8.3 HER2 does not play a significant role in perineural spread of cSCCHN   
In the era of development of multivalent antibodies, it may be suboptimal to identify a single 
receptor tyrosine kinase as a potential drug target, even in a disease process where there is 
currently no targeted therapy. A known mechanism of tumour resistance to current monoclonal 
antibody therapies is tumour evasion by activation of other kinase signalling pathways.(126) 
Thus, there is current focus on combination therapeutics targeting either proteins within the 
same family or between families in a range of malignancies.(199) Advances in antibody 
engineering technology has facilitated such approaches and several bispecific antibodies are 
currently in early clinical trial. Recently, the superiority of a tetraspecific antibody to individual 
monospecific antibodies was demonstrated in a heterogenous tumour population.(200) Beyond 
inducing antibody dependent cell cytotoxicity by recruiting FcγR positive immune cells, some 
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research groups have looked at targeting the immune system against cancer by designing dual 
antibody constructs that cross-link tumour cells and T cells via their CD3 receptors.(199) 
 
In terms of the ErbB family specifically, where the HER2 receptor is completely dependent 
and the HER3 is a partially impaired RTK, preventing heterodimerisation is a key strategy. 
Dual targeting of EGFR and ErbB2 pathways has been shown to have synergistic effect on 
cancer cell proliferation and migration in in vitro models with human cancer cell lines.(201) 
Lapatinib is a dual TKI that targets both EGFR and HER2 and has progressed to clinical trial 
in breast cancer.(202) Targeting the four members of the ERRB family in HNSCC with a mixture 
of six antibodies (pan-HER) has also recently been shown to reduce cell proliferation in vitro 
and achieve superior growth delay in a murine model compared to cetuximab or vehicle 
control.(203)  
 
Thus, given that HER2 is the preferred heterodimerisation partner for other members of the 
ErbB family, including EGFR, we sought to characterise HER2 expression in perineural spread 
to complement our finding of significant EGFR overexpression. None of 20 specimens stained 
positive for HER2 using a high affinity antibody. Although limitations in 
immunohistochemistry do exist, HER2 interpretation is subject to standardised guidelines and 
highly reproducible.(204) The 4B5 anti-HER2 antibody we used has been shown to have 
excellent sensitivity, specificity and inter-laboratory reproducibility for the detection of HER2 
status in breast cancer.(205) However, HER2 was not detectable by IHC in any of the 20 
specimens of perineural spread. We conclude that HER2 does not play a significant role in 
perineural spread of cSCCHN and does not represent a potential therapeutic target in this 
unique form of tumour metastasis.    
 
On review of the literature, there are few previous studies investigating the role of HER2 in 
squamous cell carcinoma. One study looked at co-expression patterns of ErbB receptors in 
NMSC and found HER2 to be ubiquitously expressed in all tested tissue from a mixed cohort 
of normal skin, BCCs and SCCs (n=56).(195) In a later study of 13 metastatic cSCC, HER2 was 
weakly expressed in 31% with a membrane expression in only 2 (15%) cases.(189,195) Similarly, 
ErbB2 status in mucosal HNSCC has not been well studied. In a recent study only 2/42 (5%) 
laryngeal SCCs and 2/94 (2%) oral cavity SCCs were positive for ErbB2 (HER2) over-
expression on immunohistochemistry.(206) Earlier studies have reported an inverse relationship 
between EGFR and HER2 expression although this was not observed by Maubec et al (2005) 
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in metastatic cSCC and the absence of HER 2 positivity in our cohort precluded this 
assessment.(189) 
 
The lack of HER2 expression in these tumours mechanistically is likely to lead to higher EGFR 
activation as EGFR will homodimerize in the absence of its preferred heterodimeric partner. 
Under usual circumstances EGFR activated complexes are down-regulated by internalisation 
and degradation. Our results suggest that in half of the samples of perineural spread, EGFR has 
escaped this pathway and in the absence of HER internalisation via other routes, such as the 
clathrin-independent carriers (CLIC)/glycosylphosphotidylinositol-anchored protein enriched 
compartments (GEEC) endocytosis pathway, EGFR degradation will not occur. This balance 
of receptor expression and downstream signalling consequences is an area for future 
exploration in perineural spread. Nonetheless, given our result and others in both cutaneous 
and HNSCC, it appears that HER2 is not central to the mechanism of perineural spread. 
Certainly, HER2 absence or low level of expression precludes drug targeting whether as a 
monotherapy or combination therapeutic. It is also unlikely to emerge as a valuable biomarker 
in future.       
 
8.4 HER3 and Eph receptor expression remains poorly defined in perineural spread 
cSCCHN and immunohistochemistry requires further optimisation   
HER3 expression is poorly understood in cSCCHN and not characterised at all in perineural 
spread. In one study of SCC of the cervix (n=78), immunohistochemistry for HER1-HER4 
revealed overexpression in 63% for HER1, 22% for HER2, 74% for HER3 and 80% for 
HER4.(207) Overexpression of HER2 and HER3 was associated with worse prognosis.(207) 
HER3 has previously been investigated in cSCC but observed to have consistently low level 
expression.(208) Recently, Kim (2015) suggested a potential role for HER3 in perineural 
invasion in HNSCC.(209) Expression of HER3 in HNSCC cell lines was reported and activation 
of HER3 resulted in increased migration and invasion of the tumour cells. Using a co-culture 
model, chemotactic invasion towards the DRG in a HER3 signalling dependent fashion was 
observed. In a novel neurite-tumour interaction assay the author went on to demonstrate 
inhibition of perineural migration by downregulation of HER3 expression. This recent study 
puts forward the NRG1:HER3 axis as another novel candidate for investigation in perineural 
spread cSCCHN.     
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Furthermore, comparable to dual EGFR/HER2 targeting, several studies have now shown that 
dual inhibition of HER3 and EGFR is efficacious in multiple tumour models.(200) Moreover, 
inhibition of HER3 phosphorylation has been correlated with anti-proliferative activity of 
tyrosine kinase inhibitors in colorectal, pancreatic and NSCLC cell lines, suggesting that 
optimal EGFR signalling inhibition requires simultaneous inhibition of HER3 signalling.(210) 
 
We were unfortunately unsuccessful in our initial attempts to optimise a HER3 immunostaining 
protocol for FFPE tissue to allow assessment of HER3 expression in perineural spread 
cSCCHN. The DAKO (DAK-H3-IC) monoclonal antibody used was highly specific on 
Western blot and cellular immunofluorescence studies. Despite being recognised as the most 
specific antibody for tissue staining in a recent review article, the application to 
immunohistochemistry and immunofluorescence in FFPE tissue remains challenging.(179) 
Using this antibody on the automated Ventana research platform we were unable to attain 
positive staining in any of the predicted positive tissue controls utilised within our study 
timeframe. This remains a promising area for further optimisation and future research. 
 
Similarly, despite positive findings on immunoblot and cell immunofluorescence with highly 
specific CST antibodies targeting the EphA3 and EphB4 receptors, we were unable to achieve 
specific reproducible immunostaining on positive control FFPE tissues. We anticipate ongoing 
collaboration with our colleagues in the Boyd laboratory (QIMR Berghofer) to refine antigen 
retrieval methods and other conditions for FFPE tissue. Alternative approaches could be to 
target the ephrin ligand as a surrogate marker or trial immunostaining in fresh frozen tissue 
specimens to avoid the antigenic disruption inherent in the fixation process. Again, this remains 
an area for ongoing optimisation and research in our laboratory.  
 
The multiplex fluorescent imaging we achieved with pathology standard antibodies to 
cytokeratin and myelin, is representative of an ideal technique for examining this anatomically 
unique disease process. Although such techniques have limited application in the clinical 
setting due to time and cost constraints, secondary immunofluorescence allows high resolution 
examination of different components of the nerve-tumour microenvironment in the research 
setting. We hope to apply this method to novel proteins of interest including ErbB and Eph 
receptors. As discussed earlier, it is probably the balance of RTK expression and activity that 
dictates the malignant phenotype, and the demonstrated ability to examine multiple receptors 
and their temporo-spatial relationships provides an avenue for further pursuit.    
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8.5 The biomarker expression profile of perineural spread of cSCCHN suggests 
independent or inter-dependent underlying mechanisms 
We aimed to determine the expression profile of common cancer biomarkers and correlate with 
relevant clinicopathological factors. To our knowledge, no previous study has examined the 
expression or dysregulation of the cell cycle proteins p16 or p53 in perineural spread of 
carcinoma. Equally, Ki-67 as a marker of cellular proliferation and aggressive disease has not 
previously been examined. Previous data from our institution published by Warren et al (2016) 
has consistently shown that cSCCHN with PNS is more likely to be moderately or poorly 
differentiated.(142) This was confirmed in our series with 95% specimens exhibiting moderate 
or poor differentiation. Also consistent with the natural history of this disease, a significant 
proportion of patients in our cohort had an unknown primary or an index lesion could not be 
assessed or recorded at the time of presentation with perineural disease. This is common in 
perineural spread and one of the inherent challenges for research in this field. A negative 
correlation between level of EGFR expression and degree of SCC differentiation has 
previously been reported in primary cutaneous lesions and in oral cavity SCC and other 
malignancies.(211) However, due to small numbers we were not able to explore this relationship 
in perineural spread cSCCHN in our series.   
 
Ki-67 proliferation index is a well characterised marker of cellular proliferation and aggressive 
disease course. Proliferation index has previously been used to assess perineural invasion in 
the in vitro model developed by Ayala et al (2001).(45) However, to our knowledge, no author 
has previously examined proliferation status of perineural spread at the tissue level. The 
monoclonal antibody for Ki-67 antigen is highly specific. However, interpretation of Ki-67 
staining is challenging and prone to inter-observer variability. We combated this by using two 
staining methods, a manual cell count and automated analysis using an online deconvolution 
algorithm. There was a reasonable degree of correlation between these two methods for 
specimens for diffuse tumour. The minimal numbers of tumour cells and abundance of other 
stromal and inflammatory elements in other specimens, consistent with the disease anatomy, 
limited the application of the automated method necessitating the use of standalone manual 
cell counts in these cases.  
 
The optimal Ki-67 cut-off for prognostic assessment is unknown. Values ranging between 15-
30% as a threshold for clinically significant proliferation have been suggested previously, 
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while other authors have suggested using the median value of Ki-67 labelling index as a cut-
off within a population or series.(173) In our series, median and mean values approximated 30% 
so this was applied as the threshold for highly proliferative tumours. In our cohort, 50% of 
cSCCHN with PNS had proliferation index ≥30% and were considered highly proliferative, 
with a range up to 55.4%. Several lesions (10%) had low proliferation < 15%. We conclude 
that perineural spread exhibits a spectrum of proliferation comparable to other presentations of 
cSCC and non-cutaneous SCC (verbal communication, Ian Brown, 2016). This is consistent 
with the variable clinical picture of slow to rapidly progressive disease seen in perineural 
spread. Using time from onset of neuropathic symptoms to diagnosis of perineural spread as a 
surrogate clinical marker of aggressiveness, we sought to correlate these two factors. In our 
cohort, median time to diagnosis was 4 months (range, 1-60 months) and a mean time of 
approximately 11 months. This is comparable to previous studies, which quote an average 
delay of 6-18 months from symptom onset to definitive diagnosis of perineural spread, usually 
on MR neurography.(142) Although we expected a linear correlation between Ki-67 proliferation 
index and rapidity of presentation, this was not supported by our data to statistical significance. 
There is a significant margin of error in the retrospective estimate of symptom duration by 
patients and it may be that other markers of aggressiveness may be more representative for 
future work. Irrespective, once sufficient follow-up data is available, survival analysis using 
the Kaplan-Meier method would be applicable with univariate and multivariate analyses likely 
to be informative. Ki-67 may have role in disease prognostication and allow rationalisation of 
therapy, as has recently been demonstrated in mucosal HNSCC. It has also been examined as 
an independent or combination therapeutic target in other settings.  
 
8.5.1 A subset of perineural spread is strongly positive for p16, which represents a 
potential biomarker  
To our knowledge this is the first study to assess p16 status in perineural spread cSCCHN and 
by surrogate consider the possible role of chronic HPV infection in the pathogenesis of this 
process. Nearly one third (30%) of our cohort were strongly positive for p16 and met the 
clinical threshold for p16 positivity used in mucosal HNSCC. Lower thresholds for positivity 
have been used in other studies of cSCC, which may have overestimated the incidence. 
Although there is no agreed definition, we used the method published in recent literature 
assessing primary and nodal metastatic lesions.(172) As to whether it is viral or UVR associated 
dysregulation in the p16 pathway that has led to significant overexpression in a subset of 
perineural spread cSCCHN, it is difficult to say.  Unlike other studies, we did not perform FISH 
109 
 
or PCR for the presence of high-risk HPV subtypes. Although these could be performed in 
future, the presence of viral DNA has been shown to be less clinically significant than the 
surrogate p16 marker, which is a validated prognostic factor independent of HPV status in 
oropharyngeal SCC.(152) The hypothesis that chronic viral infection and associated 
inflammation facilitates or contributes perineural invasion of carcinoma requires further 
investigation with appropriately designed studies. A potential role for neurotropic viruses in 
the mechanisms of perineural spread and even as a means of targeting therapy to the nerve 
microenvironment could also be considered in future studies.   
 
 
8.5.2. The p53 pathway appears to be dysregulated in a subset of perineural spread 
We built on earlier work by our collaborators at QIMR Berghofer by completing 
immunohistochemical staining for p53 across our cohort.(142) Reproducible specific staining 
was achieved,  which displayed one of three patterns described by previous authors in ovarian 
and colorectal cancers.(147) Importantly, staining was performed using identical methodology 
to allow pooling of data. Earlier mutational analyses have shown the TP53 gene to be mutated 
in more than 50% of cSCC with aggressive tumours, including those with incidental PNI.(132) 
In perineural spread cSCCHN we would expect a high mutational background secondary to 
UVR as observed in primary and metastatic cSCC. It is unsurprising that in our cohort an 
abnormal staining pattern for p53 was observed in 65% of specimens, with half the tumours 
exhibiting diffuse staining pattern consistent with reactive over-expression and 15% having no 
positive staining consistent with loss of function of this integral tumour suppressor gene. 
Certainly these findings support the assertion of our collaborators that the p53 pathway is 
implicated in perineural spread cSCCHN.(142) The question remains whether this is simply a 
bystander effect or a conserved signature of UVR exposure and the index lesion.  Alternatively, 
further dysregulation at the molecular level may be critically important in the processes of 
perineural invasion and spread. As with other potential biomarkers examined in our study, 
future survival analyses will be informative regarding their clinical utility as prognostic factors. 
In our study, we were also unable to establish a statistically significant correlation between 
EGFR status or localisation and any of the biomarkers examined, unfortunately limited largely 
by small numbers. In the research setting we would support ongoing acquisition of biopsies 
and staining for Ki-67, p16 and p53 in anticipation of further analyses.  
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8.6 Final discussion 
Knowledge of the molecular profile and drivers for a cancer sub-type is imperative to targeting 
therapy. Increasing research focus is centred on multivalent antibody therapy or multi-targeted 
approaches. For example, one research group recently demonstrated efficient and selective 
light-controlled tumour cell killing in vitro for cells positive for both EGFR and Ki-67 via a 
dual targeting approach.(97) Multivalent antibody therapy to the ErbB family remains the 
frontier in cancer therapy, particularly in the fight to overcome resistance. Further 
characterisation of other RTKs, including HER3 and the Eph receptor family, is needed in the 
context of perineural spread cSCCHN. In particular, based on our cell data and given the 
availability of highly specific monoclonal antibodies, suitable candidates for further research 
would include EphA2, EphB2 and EphB4.  The advantage of immunohistochemistry-based 
biomarkers is that they offer significant potential for rapid translation to clinical practice 
compared to biomarkers requiring more complicated, time-consuming and expensive methods. 
Recently, a small multi-marker panel using simple immunohistochemistry methods to evaluate 
5-hydroxymethylcytosine (5hmC), Ki-67 and p16 has shown promise as an adjunct for 
prognostication in melanoma.(212) Evidently, significant optimisation is required to achieve 
reliable reproducible staining in fixed tissue but we hope a similar panel may be applicable in 
perineural spread to better risk stratify patients and allow treatment rationalisation. Some cases 
of perineural spread progress slowly towards the brainstem and may not affect the patient in 
their lifetime if they are elderly and/or have significant comorbidities. Other cases progress 
rapidly, with significant morbidity, justifying aggressive intervention. There is a high risk of 
recurrence, particularly given the anatomical constraints of oncologic resection, and close 
clinical and radiological follow-up is required. Identification of novel biomarkers would aid 
prognostication from biopsy or resection specimens, may inform risk of progression or 
recurrence and thus allow appropriate rationalisation of therapy and informed follow-up. In 
this era of personalised medicine and technological advances, individualisation of therapy 
based on the molecular profile of a patients perineural disease is not unforeseeable.   
  
The demonstrated dysregulation of tumour suppressor genes in perineural spread is a notable 
finding. As discussed earlier, cSCC can be considered as RTK driven via EGFR signalling or 
driven by dysregulation of the p53 pathway. In our study, EGFR overexpression was almost 
universal suggesting that perineural spread cSCCHN may be derived from the former group of 
cutaneous primaries and is thus genetically similar to mucosal HNSCC. Genetic and epigenetic 
changes in epidermal and dermal cells secondary to solar UVR is certainly the principal 
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mechanism in any form of cSCC and tumour cells typically harbour driver mutations that 
reflect this. However it is evidently these changes in the context of concomitant alterations in 
the microenvironment that facilitates progression of precursor lesions to invasive SCC, and 
SCC to more malignant forms of the disease, including tumours with perineural invasion and/or 
spread.(131) Further consideration of RTK signalling in the context of the nerve-tumour 
microenvironment is required either using established in vitro models or other novel 
approaches. Loss of immune surveillance and the presence of HPV are two other risk factors, 
best demonstrated in the development of cSCC in the immunosuppressed population. Although 
immunosuppression is not seen to be a risk factor for perineural spread, the inflammatory 
infiltrate associated with PNS of cSCCHN and changes in T-cell subsets previously reported 
by our collaborators support a possibly interplay between chronic HPV infection, chronic 
inflammation, significant UVR exposure and either the p53 pathway or dysregulation EGFR 
trafficking in both cSCCHN and perineural spread of the same. This led us to consider p53 and 
p16 expression at an early stage in our investigation into perineural disease. Together with Ki-
67 proliferation index this provides an indication that there are probably diverse underlying 
mechanisms driving perineural spread of carcinoma.  
 
Our findings support a significant role for dysregulation of EGFR trafficking. As such we have 
revealed potential biomarker and also a clinically relevant therapeutic target. Larger numbers 
are certainly needed but given our tertiary centre sees 25 patients amenable to surgical resection 
per year, tissue acquisition remains an ongoing challenge. Moving into the established 
subcutaneous mouse model at an early stage is justified to ensure any benefits can be translated 
to the current generation of patients suffering from this morbid disease. We similarly anticipate 
early recruitment of patients with recalcitrant end-stage perineural disease who have either 
failed or are unsuitable for conventional therapy into a recently approved clinical trial which 
uses a dynamin inhibitor in combination with cetuximab to target EGFR at the cell surface.213-
215 Trapping the EGFR at the plasma membrane through dynamin inhibition in the perineural 
spread cohort has conceivable advantage beyond monotherapy given the significant tumour 
heterogeneity observed in our study.  
 
8.7 Future directions 
Further research is required to elucidate the underlying mechanisms of perineural spread of 
carcinoma. We have potentially uncovered an important biomarker and made a significant step 
forward in detection of EGFR overexpression. However, it is undoubtedly the interplay of 
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several mechanisms that culminate in this unique disease process. To build directly on our 
current findings we anticipate utilising existing in vitro and in vivo models as described above. 
Our collaborators at the QIMR Berghofer have utilised a DRG co-culture model and a 
subcutaneous murine model of perineural spread. Subject to ethics approval, we would also 
aim to commence a mouse study with a therapeutic anti-EGFR antibody with appropriate 
control arms. Success in the murine model may allow us to enrol select patients who have failed 
conventional therapy to a recently approved phase I clinical trial targeting the EGFR with 
cetuximab in combination with prochlorperazine (CESTEM trial).215 Reversing the 
heterogeneity of the cohort by co-administering a dynamin inhibitor could be expected to 
provide additional benefit, as shown in a proof of mechanism study recently by our 
laboratory.213-215 
 
9.0 Conclusion 
Our findings clearly have direct clinical implications. A role for EGFR in perineural spread is 
supported while HER2 does not appear to be involved. Subcellular localization of the receptor 
may have implications in targeting therapy and overcoming resistance to current therapies. The 
EGFR may represent an opportunity to more accurately predict perineural spread from the 
index lesion, prognosticate patients, rationalise therapy and inform follow-up. Knowledge of 
the co-existing biomarker profile and future survival analyses may shed further light. Existing 
targeted therapies to the epidermal growth factor receptor could be re-purposed for use in 
perineural spread and clinical trials for novel/combination therapies could be extended to 
patients with recurrent and/or unresectable perineural spread of carcinoma. Ultimately, it is 
hoped we can improve patient morbidity and mortality not only in cutaneous squamous cell 
carcinoma of the head and neck, but in other neurotropic malignancy.  
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11.0 Appendix A 
11.1 Appendix A Representative confocal imaging of cell immunofluorescence 
 
 
Figure A1 Confocal immunofluorescence images of human cell lines stained with antibody to EphA2 
receptor. Images are displayed from left to right as isolated blue channel (DAPI stained nuclei), isolated green channel 
(anti-EphA2) and merge channel. Secondary anti-rabbit Alexa-488 was used. Negative control (Neg) was A431 cells 
labelled with secondary antibody only (lower panel). Scale bar = 20μm. 
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Figure A2 Confocal immunofluorescence images of human cell lines stained with antibody to EphA3 
receptor. Images are displayed from left to right as isolated blue channel (DAPI stained nuclei), isolated green channel 
(anti-EphA3) and merge channel. Secondary anti-rabbit Alexa-488 was used. Negative control (Neg) was A431 cells 
labelled with secondary antibody only (lower panel). Scale bar = 20μm 
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Figure A3 Confocal immunofluorescence images of human cell lines stained with antibody to EphB1 
receptor. Images are displayed from left to right as isolated blue channel (DAPI stained nuclei), isolated green channel 
(anti-EphB2) and merge channel. Secondary anti-mouse Alexa-488 was used. Negative control (Neg) was A431 cells 
labelled with secondary antibody only (lower panel). Scale bar = 20μm. 
 
 
 
 
 
H
E
K
a
C
O
LO
1
6
A
4
3
1
N
eg
DAPI MergeEphB1
134 
 
 
  
Figure A4 Confocal immunofluorescence images of human cell lines stained with antibody to EphB2 
receptor. Images are displayed from left to right as isolated blue channel (DAPI stained nuclei), isolated red (anti-EphB2) 
channel and merge channel. Secondary anti-goat Alexa-555 was used. Negative control (Neg) was HEKa cells labelled with 
secondary antibody only (lower panel). Scale bar = 20μm. 
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Figure A5 Confocal immunofluorescence images of human cell lines stained with antibody to EphB4 
receptor. Images are displayed from left to right as isolated blue channel (DAPI stained nuclei), isolated green (anti-EphB4) 
channel and merge channel. Secondary anti-rabbit Alexa-488 was used. Negative control (Neg) was A431 cells labelled with 
secondary antibody only (lower panel). Scale bar = 20μm. 
